

## CORRECTED VERSION

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
18 May 2000 (18.05.2000)

PCT

(10) International Publication Number  
WO 00/27363 A1(51) International Patent Classification<sup>7</sup>: A61K 9/14, 9/72

(21) International Application Number: PCT/US99/26799

(22) International Filing Date:  
12 November 1999 (12.11.1999)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/190,138 12 November 1998 (12.11.1998) US

(71) Applicant: NANOSYSTEMS [US/US]; 3000 Horizon Drive, King of Prussia, PA 19406 (US).

(72) Inventors: BOSCH, H., William; 237 Rodney Circle, Bryn Mawr, PA 19010 (US). OSTRANDER, Kevin, D.; 227 Sunrise Road, Reading, PA 19606 (US). COOPER, Eugene, R.; 2621 Crum Creek Drive, Berwyn, PA 19312 (US).

(74) Agents: SCHAFER, Michele, M. et al.; Foley &amp; Lardner, Suite 500, 3000 K Street, NW, Washington, DC 20007-5109 (US).

(81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE,

ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

## Published:

- With international search report.
- With amended claims.

Date of publication of the amended claims: 13 July 2000

(48) Date of publication of this corrected version:  
30 November 2000

## (15) Information about Correction:

see PCT Gazette No. 48/2000 of 30 November 2000, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 00/27363 A1

(54) Title: AEROSOLS COMPRISING NANOPARTICLE DRUGS

(57) Abstract: The invention discloses aqueous dispersions of nanoparticulate aerosol formulations, dry powder nanoparticulate aerosol formulation, propellant-based aerosol formulations, methods of using the formulations in aerosol delivery devices, and methods of making such formulations. The nanoparticles of the aqueous dispersions or dry powder formulations comprise insoluble drug particles having a surface modifier on the surface thereof.

BEST AVAILABLE COPY

## AEROSOLS COMPRISING NANOPARTICLE DRUGS

### FIELD OF THE INVENTION

The present invention is directed to aerosol formulations of nanoparticulate drug compositions, and methods of making and using such aerosol formulations.

### BACKGROUND OF THE INVENTION

The route of administration of a drug substance can be critical to its pharmacological effectiveness. Various routes of administration exist, and all have their own advantages and disadvantages. Oral drug delivery of tablets, capsules, liquids, and the like is the most convenient approach to drug delivery, but many drug compounds are not amenable to oral administration. For example, modern protein drugs which are unstable in the acidic gastric environment or which are rapidly degraded by proteolytic enzymes in the digestive tract are poor candidates for oral administration. Similarly, poorly soluble compounds which do not dissolve rapidly enough to be orally absorbed are likely to be ineffective when given as oral dosage forms. Oral administration can also be undesirable because drugs which are administered orally are generally distributed to all tissues in the body, and not just to the intended site of pharmacological activity.

Alternative types of systemic administration are subcutaneous or intravenous injection. This approach avoids the gastrointestinal tract and therefore can be an effective route for delivery of proteins and peptides. However, these routes of administration have a low rate of patient compliance, especially for drugs such as insulin which must be administered one or more times daily. Additional alternative methods of drug delivery have been developed including transdermal, rectal, vaginal, intranasal, and pulmonary delivery.

Nasal drug delivery relies on inhalation of an aerosol through the nose so that active drug substance can reach the nasal mucosa. Drugs intended for systemic activity can be absorbed into the bloodstream because the nasal mucosa is highly vascularized. Alternatively, if the drug is intended to act topically, it is delivered directly to the site of activity and does not have to distribute throughout the body; hence,

relatively low doses may be used. Examples of such drugs are decongestants, antihistamines, and anti-inflammatory steroids for seasonal allergic rhinitis.

Pulmonary drug delivery relies on inhalation of an aerosol through the mouth and throat so that the drug substance can reach the lung. For systemically active drugs, it is desirable for the drug particles to reach the alveolar region of the lung, whereas drugs which act on the smooth muscle of the conducting airways should preferentially deposit in the bronchiole region. Such drugs can include beta-agonists, anticholinergics, and corticosteroids.

10 **Devices Used For Nasal and Pulmonary Drug Delivery**

Drugs intended for intranasal delivery (systemic and local) can be administered as aqueous solutions or suspensions, as solutions or suspensions in halogenated hydrocarbon propellants (pressurized metered-dose inhalers), or as dry powders. Metered-dose spray pumps for aqueous formulations, pMDIs, and DPIs for nasal delivery, are available from, for example, Valois of America or Pfeiffer of America.

Drugs intended for pulmonary delivery can also be administered as aqueous formulations, as suspensions or solutions in halogenated hydrocarbon propellants, or as dry powders. Aqueous formulations must be aerosolized by liquid nebulizers employing either hydraulic or ultrasonic atomization, propellant-based systems require suitable pressurized metered-dose inhalers (pMDIs), and dry powders require dry powder inhaler devices (DPIs) which are capable of dispersing the drug substance effectively. For aqueous and other non-pressurized liquid systems, a variety of nebulizers (including small volume nebulizers) are available to aerosolize the formulations. Compressor-driven nebulizers incorporate jet technology and use compressed air to generate the liquid aerosol. Such devices are commercially available from, for example, Healthdyne Technologies, Inc.; Invacare, Inc.; Mountain Medical Equipment, Inc.; Pari Respiratory, Inc.; Mada Medical, Inc.; Puritan-Bennet; Schuco, Inc., DeVilbiss Health Care, Inc.; and Hospitak, Inc. Ultrasonic nebulizers rely on mechanical energy in the form of vibration of a piezoelectric crystal to generate respirable

liquid droplets and are commercially available from, for example, Omron Healthcare, Inc. and DeVilbiss Health Care, Inc.

A propellant driven inhaler (pMDI) releases a metered dose of medicine upon each actuation. The medicine is formulated as a suspension or solution of a drug substance in a suitable propellant such as a halogenated hydrocarbon. pMDIs are 5 described in, for example, Newman, S. P., *Aerosols and the Lung*, Clarke et al., eds., pp. 197-224 (Butterworths, London, England, 1984).

Dry powder inhalers (DPIs), which involve deaggregation and aerosolization of dry powders, normally rely upon a burst of inspired air that is drawn 10 through the unit to deliver a drug dosage. Such devices are described in, for example, U.S. Pat. No. 4,807,814, which is directed to a pneumatic powder ejector having a suction stage and an injection stage; SU 628930 (Abstract), describing a hand-held powder disperser having an axial air flow tube; Fox et al., *Powder and Bulk Engineering*, pages 15 33-36 (March 1988), describing a venturi eductor having an axial air inlet tube upstream of a venturi restriction; EP 347 779, describing a hand-held powder disperser having a collapsible expansion chamber; and U.S. Pat. No. 5,785,049, directed to dry powder delivery devices for drugs.

#### Droplet/Particle Size Determines Deposition Site

20 In developing a therapeutic aerosol, the aerodynamic size distribution of the inhaled particles is the single most important variable in defining the site of droplet or particle deposition in the patient; in short, it will determine whether drug targeting succeeds or fails. See P. Byron, "Aerosol Formulation, Generation, and Delivery Using Nonmetered Systems," *Respiratory Drug Delivery*, 144-151, 144 (CRC Press, 1989).  
25 Thus, a prerequisite in developing a therapeutic aerosol is a preferential particle size. The deposition of inhaled aerosols involves different mechanisms for different size particles. D. Swift (1980); Parodi et al., "Airborne Particles and Their Pulmonary Deposition," in *Scientific Foundations of Respiratory Medicine*, Scaddings et al. (eds.), pp. 545-557

(W.B. Saunders, Philadelphia, 1981); J. Heyder, "Mechanism of Aerosol Particle Deposition," *Chest*, 80:820-823 (1981).

Generally, inhaled particles are subject to deposition by one of two mechanisms: impaction, which usually predominates for larger particles, and 5 sedimentation, which is prevalent for smaller particles. Impaction occurs when the momentum of an inhaled particle is large enough that the particle does not follow the air stream and encounters a physiological surface. In contrast, sedimentation occurs primarily in the deep lung when very small particles which have traveled with the inhaled air stream encounter physiological surfaces as a result of random diffusion within the air 10 stream. For intranasally administered drug compounds which are inhaled through the nose, it is desirable for the drug to impact directly on the nasal mucosa; thus, large (ca. 5 to 100  $\mu\text{m}$ ) particles or droplets are generally preferred for targeting of nasal delivery.

Pulmonary drug delivery is accomplished by inhalation of an aerosol through the mouth and throat. Particles having aerodynamic diameters of greater than 15 about 5 microns generally do not reach the lung; instead, they tend to impact the back of the throat and are swallowed and possibly orally absorbed. Particles having diameters of about 2 to about 5 microns are small enough to reach the upper- to mid-pulmonary region (conducting airways), but are too large to reach the alveoli. Even smaller particles, *i.e.*, about 0.5 to about 2 microns, are capable of reaching the alveolar region. Particles having 20 diameters smaller than about 0.5 microns can also be deposited in the alveolar region by sedimentation, although very small particles may be exhaled.

Problems with Conventional Aerosol Compositions and Methods

Conventional techniques are extremely inefficient in delivering agents to the lung for a variety of reasons. Prior to the present invention, attempts to develop respirable aqueous suspensions of poorly soluble drugs have been largely unsuccessful.

5 For example, it has been reported that ultrasonic nebulization of a suspension containing fluorescein and latex drug spheres, representing insoluble drug particles, resulted in only 1% aerosolization of the particles, while air-jet nebulization resulted in only a fraction of particles being aerosolized. Susan L. Tiano, "Functionality Testing Used to Rationally Assess Performance of a Model Respiratory Solution or Suspension in a Nebulizer,"

10 Dissertation Abstracts International, 56/12-B, pp. 6578 (1995). Another problem encountered with nebulization of liquid formulations prior to the present invention was the long (4-20 min) period of time required for administration of a therapeutic dose. Long administration times are required because conventional liquid formulations for nebulization are very dilute solutions or suspensions of micronized drug substance.

15 Prolonged administration times are undesirable because they lessen patient compliance and make it difficult to control the dose administered. Lastly, aerosol formulations of micronized drug are not feasible for deep lung delivery of insoluble compounds because the droplets needed to reach the alveolar region (0.5 to 2 microns) are too small to accommodate micronized drug crystals, which are typically 2-3 microns or more in

20 diameter.

Conventional pMDIs are also inefficient in delivering drug substance to the lung. In most cases, pMDIs consist of suspensions of micronized drug substance in halogenated hydrocarbons such as chlorofluorocarbons (CFCs) or hydrofluoroalkanes (HFAs). Actuation of the pMDI results in delivery of a metered dose of drug and propellant, both of which exit the device at high velocities because of the propellant pressures. The high velocity and momentum of the drug particles results in a high degree of oropharyngeal impaction as well as loss to the device used to deliver the agent. These losses lead to variability in therapeutic agent levels and poor therapeutic control. In addition, oropharyngeal deposition of drugs intended for topical administration to the

conducting airways (such as corticosteroids) can lead to systemic absorption with resultant undesirable side effects. Additionally, conventional micronization (air-jet milling) of pure drug substance can reduce the drug particle size to no less than about 2-3 microns. Thus, the micronized material typically used in pMDIs is inherently unsuitable 5 for delivery to the alveolar region and is not expected to deposit below the central bronchiole region of the lung.

Prior to the present invention, delivery of dry powders to the lung typically used micronized drug substance. In the dry powder form, micronized substances tend to have substantial interparticle electrostatic attractive forces which prevent the powders 10 from flowing smoothly and generally make them difficult to disperse. Thus, two key challenges to pulmonary delivery of dry powders are the ability of the device to accurately meter the intended dose and the ability of the device to fully disperse the micronized particles. For many devices and formulations, the extent of dispersion is dependent upon the patient's inspiration rate, which itself may be variable and can lead to 15 a variability in the delivered dose.

Delivery of drugs to the nasal mucosa can also be accomplished with aqueous, propellant-based, or dry powder formulations. However, absorption of poorly soluble drugs can be problematic because of mucociliary clearance which transports deposited particles from the nasal mucosa to the throat where they are swallowed. 20 Complete clearance generally occurs within about 15-20 minutes. Thus, poorly soluble drugs which do not dissolve within this time frame are unavailable for either local or systemic activity.

The development of aerosol drug delivery systems has been hampered by the inherent instability of aerosols, the difficulty of formulating dry powder and aqueous 25 aerosols of water-insoluble drugs, and the difficulty of designing an optimal drug particle size for an aerosol drug delivery system. There is a need in the art for aerosols that deliver an optimal dosage of essentially insoluble drugs throughout the respiratory tract or nasal cavity. The present invention satisfies these needs.

## SUMMARY OF THE INVENTION

The present invention is directed to aqueous, propellant-based, and dry powder aerosols of nanoparticulate compositions, for pulmonary and nasal delivery, in which essentially every inhaled particle contains at least one nanoparticulate drug particle.

5 The drug is highly water-insoluble. Preferably, the nanoparticulate drug has an effective average particle size of about 1 micron or less. This invention is an improvement of the nanoparticulate aerosol formulations described in pending U.S. Application Serial No. 08/984,216, filed on October 9, 1997, for "Aerosols Containing Nanoparticulate Dispersions," specifically incorporated by reference. Non-aerosol preparations of

10 submicron sized water-insoluble drugs are described in U.S. Patent No. 5,145,684, specifically incorporated herein by reference.

### **A. Aqueous Aerosol Formulations**

The present invention encompasses aqueous formulations containing nanoparticulate drug particles. For aqueous aerosol formulations, the drug may be present at a concentration of about 0.05 mg/mL up to about 600 mg/mL. Such formulations provide effective delivery to appropriate areas of the lung or nasal cavities. In addition, the more concentrated aerosol formulations (*i.e.*, for aqueous aerosol formulations, about 10 mg/mL up to about 600 mg/mL) have the additional advantage of enabling large quantities of drug substance to be delivered to the lung in a very short period of time, *e.g.*, about 1 to about 2 seconds (1 puff) as compared to the conventional 4-20 min. administration period.

### **B. Dry Powder Aerosol Formulations**

Another embodiment of the invention is directed to dry powder aerosol formulations comprising drug particles for pulmonary and nasal administration. Dry powders, which can be used in both DPIs and pMDIs, can be made by spray-drying aqueous nanoparticulate drug dispersions. Alternatively, dry powders containing nanoparticulate drug can be made by freeze-drying nanoparticulate drug dispersions.

Combinations of spray-dried and freeze-dried nanoparticulate drug powders can be used in DPIs and pMDIs. For dry powder aerosol formulations, the drug may be present at a concentration of about 0.05 mg/g up to about 990 mg/g. In addition, the more concentrated aerosol formulations (*i.e.*, for dry powder aerosol formulations about 10 mg/g up to about 990 mg/g) have the additional advantage of enabling large quantities of drug substance to be delivered to the lung in a very short period of time, *e.g.*, about 1 to about 2 seconds (1 puff).

### 1. Spray-Dried Powders Containing Nanoparticulate Drug

10 Powders comprising nanoparticulate drug can be made by spray-drying aqueous dispersions of a nanoparticulate drug and a surface modifier to form a dry powder which consists of aggregated drug nanoparticles. The aggregates can have a size of about 1 to about 2 microns which is suitable for deep lung delivery. The aggregate particle size can be increased to target alternative delivery sites, such as the upper 15 bronchial region or nasal mucosa by increasing the concentration of drug in the spray-dried dispersion or by increasing the droplet size generated by the spray dryer.

20 Alternatively, the aqueous dispersion of drug and surface modifier can contain a dissolved diluent such as lactose or mannitol which, when spray dried, forms respirable diluent particles, each of which contains at least one embedded drug nanoparticle and surface modifier. The diluent particles with embedded drug can have a particle size of about 1 to about 2 microns, suitable for deep lung delivery. In addition, the diluent particle size can be increased to target alternate delivery sites, such as the upper bronchial region or nasal mucosa by increasing the concentration of dissolved 25 diluent in the aqueous dispersion prior to spray drying, or by increasing the droplet size generated by the spray dryer.

Spray-dried powders can be used in DPIs or pMDIs, either alone or combined with freeze-dried nanoparticulate powder. In addition, spray-dried powders containing drug nanoparticles can be reconstituted and used in either jet or ultrasonic nebulizers to generate aqueous dispersions having respirable droplet sizes, where each

droplet contains at least one drug nanoparticle. Concentrated nanoparticulate dispersions may also be used in these aspects of the invention.

## 2. Freeze-Dried Powders Containing Nanoparticulate Drug

5 Nanoparticulate drug dispersions can also be freeze-dried to obtain powders suitable for nasal or pulmonary delivery. Such powders may contain aggregated nanoparticulate drug particles having a surface modifier. Such aggregates may have sizes within a respirable range, *i.e.*, about 2 to about 5 microns. Larger aggregate particle sizes can be obtained for targeting alternate delivery sites, such as the nasal mucosa.

10 Freeze dried powders of the appropriate particle size can also be obtained by freeze drying aqueous dispersions of drug and surface modifier, which additionally contain a dissolved diluent such as lactose or mannitol. In these instances the freeze dried powders consist of respirable particles of diluent, each of which contains at least one embedded drug nanoparticle.

15 Freeze-dried powders can be used in DPIs or pMDIs, either alone or combined with spray-dried nanoparticulate powder. In addition, freeze-dried powders containing drug nanoparticles can be reconstituted and used in either jet or ultrasonic nebulizers to generate aqueous dispersions having respirable droplet sizes, where each droplet contains at least one drug nanoparticle. Concentrated nanoparticulate dispersions 20 may also be used in these aspects of the invention.

## C. Propellant-Based Formulations

25 Yet another embodiment of the invention is directed to a process and composition for propellant-based systems comprising nanoparticulate drug particles and a surface modifier. Such formulations may be prepared by wet milling the coarse drug substance and surface modifier in liquid propellant, either at ambient pressure or under high pressure conditions. Alternatively, dry powders containing drug nanoparticles may be prepared by spray-drying or freeze-drying aqueous dispersions of drug nanoparticles and the resultant powders dispersed into suitable propellants for use in conventional

pMDIs. Such nanoparticulate pMDI formulations can be used for either nasal or pulmonary delivery. For pulmonary administration, such formulations afford increased delivery to the deep lung regions because of the small (*i.e.*, about 1 to about 2 microns) particle sizes available from these methods. Concentrated aerosol formulations can also 5 be employed in pMDIs.

#### D. Methods of Making Aerosol Formulations

The invention also provides methods for making an aerosol of nanoparticulate compositions. The nanoparticulate dispersions used in making aqueous 10 aerosol compositions can be made by wet milling or by precipitation methods known in the art. Dry powders containing drug nanoparticles can be made by spray drying or freeze-drying aqueous dispersions of drug nanoparticles. The dispersions used in these systems may or may not contain dissolved diluent material prior to drying. Additionally, both pressurized and non-pressurized milling operations can be employed to make 15 nanoparticulate drug compositions in non-aqueous systems.

In a non-aqueous, non-pressurized milling system, a non-aqueous liquid which has a vapor pressure of 1 atm or less at room temperature is used as a milling medium and may be evaporated to yield dry nanoparticulate drug and surface modifier. The non-aqueous liquid may be, for example, a high-boiling halogenated hydrocarbon. 20 The dry nanoparticulate drug composition thus produced may then be mixed with a suitable propellant or propellants and used in a conventional pMDI.

Alternatively, in a pressurized milling operation, a non-aqueous liquid which has a vapor pressure > 1 atm at room temperature is used as a milling medium for making a nanoparticulate drug and surface modifier composition. Such a liquid may be, 25 for example, a halogenated hydrocarbon propellant which has a low boiling point. The resultant nanoparticulate composition can then be used in a conventional pMDI without further modification, or can be blended with other suitable propellants. Concentrated aerosols may also be made via such methods.

E. Methods of Using Nanoparticulate Aerosol Formulations

In yet another aspect of the invention, there is provided a method of treating a mammal comprising: (1) forming an aerosol of a dispersion (either aqueous or powder) of nanoparticles, wherein the nanoparticles comprise an insoluble drug having a surface modifier on the surface thereof, and (2) administering the aerosol to the pulmonary or nasal cavities of the mammal. Concentrated aerosol formulations may also be used in such methods.

Another embodiment of the invention provides a method of diagnosing a mammal comprising: (1) forming an aerosol of a dispersion (either aqueous or dry) of nanoparticles, wherein the nanoparticles comprise an insoluble diagnostic agent having a surface modifier; (2) administering the aerosol to the pulmonary or nasal cavities of the mammal; and (3) imaging the diagnostic agent in the pulmonary or nasal system. Concentrated aerosol formulations can also be employed in such diagnostic methods.

Both the foregoing general description and the following detailed description are exemplary and explanatory and are intended to provide further explanation of the invention as claimed. Other objects, advantages, and novel features will be readily apparent to those skilled in the art from the following detailed description of the invention.

20

BRIEF DESCRIPTION OF THE FIGURES

Figure 1: Shows an *in vitro* deposition pattern of a concentrated aerosolized beclomethasone dipropionate dispersion from an ultrasonic nebulizer.

Figure 2: Shows an *in vitro* deposition pattern of a concentrated aerosolized beclomethasone dipropionate dispersion from a jet nebulizer.

25 Figure 3: Shows the aerodynamic volume distribution diameter of a spray-dried naproxen aerosol (2% (w/w) naproxen).

Figure 4: Shows a scanning electron micrograph of spray-dried naproxen aerosol particles (aggregated naproxen/polyvinylpyrrolidone (surface modifier)

nanoparticles, demonstrating the overall uniformity of size and the spherical nature of the particles.

Figure 5: Shows the aerodynamic volume distribution diameter of a spray-dried naproxen aerosol (5% (w/w) naproxen).

5 Figure 6: Shows the aerodynamic volume distribution diameter of a spray-dried triamcinolone acetonide (TA) aerosol (10% (w/w) TA).

Figure 7: Shows two photomicrographs: Fig. 8(A) shows spray-dried nanoparticulate budesonide particles, and Fig. 8(B) shows particles of micronized budesonide.

10 Figure 8: Shows the particle size distribution (by volume) of a reconstituted freeze-dried anti-emetic aerosol containing dextrose diluent.

Figure 9: Shows the particle size distribution of a reconstituted freeze-dried anti-emetic aerosol containing mannitol diluent.

Figure 10: Shows a scanning electron micrograph of nanoparticulate TA milled in a non-pressurized propellant system.

15

#### DETAILED DESCRIPTION OF THE INVENTION

##### **A. Aerosol Formulations**

20 The compositions of the invention are aerosols which contain drug nanoparticles. Aerosols can be defined as colloidal systems consisting of very finely divided liquid droplets or dry particles dispersed in and surrounded by a gas. Both liquid and dry powder aerosol compositions are encompassed by the invention.

### 1. Nanoparticulate Drug and Surface Modifier Particle Size

Preferably, the compositions of the invention contain nanoparticles which have an effective average particle size of less than about 1000 nm, more preferably less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 100 nm, or less than about 50 nm, as measured by light-scattering methods. By "an effective average particle size of less than about 1000 nm" it is meant that at least 50% of the drug particles have a weight average particle size of less than about 1000 nm when measured by light scattering techniques. Preferably, at least 70% of the drug particles have an average particle size of less than about 1000 nm, more preferably at least 90% of the drug particles have an average particle size of less than about 1000 nm, and even more preferably at least about 95% of the particles have a weight average particle size of less than about 1000 nm.

### 2. Concentration of Nanoparticulate Drug

For aqueous aerosol formulations, the nanoparticulate agent is present at a concentration of about 0.05 mg/mL up to about 600 mg/mL. For dry powder aerosol formulations, the nanoparticulate agent is present at a concentration of about 0.05 mg/g up to about 990 mg/g, depending on the desired drug dosage. Concentrated nanoparticulate aerosols, defined as containing a nanoparticulate drug at a concentration of about 10 mg/mL up to about 600 mg/mL for aqueous aerosol formulations, and about 10 mg/g up to about 990 mg/g for dry powder aerosol formulations, are specifically encompassed by the present invention. Such formulations provide effective delivery to appropriate areas of the lung or nasal cavities in short administration times, *i.e.*, less than about 15 seconds as compared to administration times of up to 4 to 20 minutes as found in conventional pulmonary nebulizer therapies.

### 25 3. *In Vivo* Deposition of Inhaled Aerosols

Aerosols intended for delivery to the nasal mucosa are inhaled through the nose. For optimal delivery to the nasal cavities, inhaled particle sizes of about 5 to about 100 microns are useful, with particle sizes of about 30 to about 60 microns being

preferred. For nasal delivery, a larger inhaled particle size is desired to maximize impaction on the nasal mucosa and to minimize or prevent pulmonary deposition of the administered formulation. Inhaled particles may be defined as liquid droplets containing dissolved drug, liquid droplets containing suspended drug particles (in cases where the drug is insoluble in the suspending medium), dry particles of pure drug substance, aggregates of drug nanoparticles, or dry particles of a diluent which contain embedded drug nanoparticles.


For delivery to the upper respiratory region, inhaled particle sizes of about 2 to about 10 microns are preferred, more preferred is about 2 to about 6 microns.

Delivery to the upper respiratory region may be desirable for drugs such as bronchodilators or corticosteroids that are to act locally. This is because drug particles deposited in the upper respiratory tract can dissolve and act on the smooth muscle of the airway, rather than being absorbed into the bloodstream of the patient. However, the goal for some inhaled drugs is systemic delivery, such as in cases of proteins or peptides which are not amenable to oral administration. It is preferred that drugs intended for systemic administration be delivered to the alveolar region of the lung, because 99.99% of the available surface area for drug absorption is located in the peripheral alveoli. Thus, with administration to the alveolar region, rapid absorption can be realized. For delivery to the deep lung (alveolar) region, inhaled particle sizes of less than about 2 microns are preferred.

#### 4. Aqueous Aerosols

Aqueous formulations of the present invention consist of colloidal dispersions of water-insoluble nanoparticulate drug in an aqueous vehicle which are aerosolized using air-jet or ultrasonic nebulizers. The advantages of the present invention can best be understood by comparing the sizes of nanoparticulate and conventional micronized drug particles with the sizes of liquid droplets produced by conventional nebulizers. Conventional micronized material is generally about 2 to about 5 microns or more in diameter and is approximately the same size as the liquid droplet size produced by medical nebulizers. In contrast, nanoparticulate drug particles are substantially smaller

than the droplets in such an aerosol. Thus, aerosols containing nanoparticulate drug particles improve drug delivery efficiency because they contain a higher number of drug particles per unit dose such that each aerosolized droplet contains active drug substance.



10

Aqueous Suspension of  
Micronized Drug Substance

Colloidal Dispersion of  
Drug Nanoparticles

Thus, with administration of the same dosages of nanoparticulate and  
15 micronized drug, more lung or nasal cavity surface area is covered by the aerosol  
formulation containing nanoparticulate drug.

Another advantage of the present invention is that it permits water-insoluble drug compounds to be delivered to the deep lung via nebulization of aqueous formulations. Conventional micronized drug substance is too large to reach the peripheral  
20 lung regardless of the size of the droplet produced by the nebulizer, but the present invention permits nebulizers which generate very small (about 0.5 to about 2 microns) aqueous droplets to deliver water-insoluble drugs in the form of nanoparticles to the alveoli. One example of such devices is the Circulaire® (Westmed Corp., Tucson, AZ).

Yet another advantage of the present invention is that ultrasonic nebulizers  
25 can be used to deliver water-insoluble drugs to the lung. Unlike conventional micronized material, nanoparticulate drug particles are readily aerosolized and show good *in vitro* deposition characteristics. A specific advantage of the present invention is that it permits water-insoluble drugs to be aerosolized by ultrasonic nebulizers which require the drug substance to pass through very fine orifices to control the size of the aerosolized droplets.  
30 While conventional drug material would be expected to occlude the pores, nanoparticulate drug particles are much smaller and can pass through the pores without difficulty.

Another advantage of the present invention is the enhanced rate of dissolution of water-insoluble drugs. Since dissolution rate is a function of the total surface area of drug substance to be dissolved, more finely divided drug particles (e.g., nanoparticles) have much faster dissolution rates than conventional micronized drug particles. This can result in more rapid absorption of inhaled drugs. For nasally administered drugs it can result in more complete absorption of the dose, since with a nanoparticulate drug dose the particles can dissolve rapidly and completely before being cleared via the mucociliary mechanism.

10

## 5. Dry Powder Aerosol Formulations

15


The invention is also directed to dry powders which contain nanoparticulate compositions for pulmonary or nasal delivery. The powders may consist of respirable aggregates of nanoparticulate drug particles, or of respirable particles of a diluent which contains at least one embedded drug nanoparticle. Powders containing nanoparticulate drug particles can be prepared from aqueous dispersions of nanoparticles by removing the water via spray-drying or lyophilization (freeze drying). Spray-drying is less time consuming and less expensive than freeze-drying, and therefore more cost-effective. However, certain drugs, such as biologicals benefit from lyophilization rather than spray-drying in making dry powder formulations.

20

Dry powder aerosol delivery devices must be able to accurately, precisely, and repeatably deliver the intended amount of drug. Moreover, such devices must be able to fully disperse the dry powder into individual particles of a respirable size. Conventional micronized drug particles of 2-3 microns in diameter are often difficult to meter and disperse in small quantities because of the electrostatic cohesive forces inherent in such powders. These difficulties can lead to loss of drug substance to the delivery device as well as incomplete powder dispersion and sub-optimal delivery to the lung. Many drug compounds, particularly proteins and peptides, are intended for deep lung delivery and systemic absorption. Since the average particle sizes of conventionally prepared dry powders are usually in the range of 2-3 microns, the fraction of material

which actually reaches the alveolar region may be quite small. Thus, delivery of micronized dry powders to the lung, especially the alveolar region, is generally very inefficient because of the properties of the powders themselves.

The dry powder aerosols which contain nanoparticulate drugs can be made smaller than comparable micronized drug substance and, therefore, are appropriate for efficient delivery to the deep lung. Moreover, aggregates of nanoparticulate drugs are spherical in geometry and have good flow properties, thereby aiding in dose metering and deposition of the administered composition in the lung or nasal cavities.



20 Dry nanoparticulate compositions can be used in both DPIs and pMDIs.

(In this invention, "dry" refers to a composition having less than about 5% water.)

## 6. Propellant-Based Aerosols

Another embodiment of the invention is directed to a process and composition for propellant-based MDIs containing nanoparticulate drug particles. pMDIs can comprise either discrete nanoparticles of drug and surface modifier, aggregates of nanoparticles of drug and surface modifier, or inactive diluent particles containing embedded nanoparticles. pMDIs can be used for targeting the nasal cavity, the conducting airways of the lung, or the alveoli. Compared to conventional formulations, the present invention affords increased delivery to the deep lung regions because the inhaled nanoparticulate drug particles are smaller than conventional micronized material (< 2  $\mu\text{m}$ ) and are distributed over a larger mucosal or alveolar surface area as compared to micronized drugs.

Nanoparticulate drug pMDIs of the present invention can utilize either chlorinated or non-chlorinated propellants. Concentrated nanoparticulate aerosol formulations can also be employed in pMDIs.

5      **B.      Methods of Making Aerosol Formulations**

The nanoparticulate drug compositions for aerosol administration can be made by, for example, (1) nebulizing an aqueous dispersion of nanoparticulate drug, obtained by either grinding or precipitation; (2) aerosolizing a dry powder of aggregates of nanoparticulate drug and surface modifier (the aerosolized composition may 10 additionally contain a diluent); or (3) aerosolizing a suspension of nanoparticulate drug or drug aggregates in a non-aqueous propellant. The aggregates of nanoparticulate drug and surface modifier, which may additionally contain a diluent, can be made in a non-pressurized or a pressurized non-aqueous system. Concentrated aerosol formulations may 15 also be made via such methods.

1.      **Aqueous Milling to obtain Nanoparticulate Drug Dispersions**

Milling of aqueous drug to obtain nanoparticulate drug is described in the '684 patent. In sum, drug particles are dispersed in a liquid dispersion medium and 20 mechanical means is applied in the presence of grinding media to reduce the particle size of the drug to the desired effective average particle size. The particles can be reduced in size in the presence of one or more surface modifiers. Alternatively, the particles can be contacted with one or more surface modifiers after attrition. Other compounds, such as a diluent, can be added to the drug/surface modifier composition during the size reduction 25 process. Dispersions can be manufactured continuously or in a batch mode.

2.      **Precipitation to Obtain Nanoparticulate Drug Compositions**

Another method of forming the desired nanoparticle dispersion is by 30 microprecipitation. This is a method of preparing stable dispersions of drugs in the presence of one or more surface modifiers and one or more colloid stability enhancing

surface active agents free of any trace toxic solvents or solubilized heavy metal impurities. Such a method comprises, for example, (1) dissolving the drug in a suitable solvent with mixing; (2) adding the formulation from step (1) with mixing to a solution comprising at least one surface modifier to form a clear solution; and (3) precipitating the 5 formulation from step (2) with mixing using an appropriate nonsolvent. The method can be followed by removal of any formed salt, if present, by dialysis or diafiltration and concentration of the dispersion by conventional means. The resultant nanoparticulate drug dispersion can be utilized in liquid nebulizers or processed to form a dry powder for use in a DPI or pMDI.

10

### 3. Non-Aqueous Non-Pressurized Milling Systems

In a non-aqueous, non-pressurized milling system, a non-aqueous liquid having a vapor pressure of about 1 atm or less at room temperature and in which the drug substance is essentially insoluble is used as a wet milling medium to make a 15 nanoparticulate drug composition. In such a process, a slurry of drug and surface modifier is milled in the nonaqueous medium to generate nanoparticulate drug particles. Examples of suitable non-aqueous media include ethanol, trichloromonofluoromethane (CFC-11), and dichlorotetrafluoroethane (CFC-114). An advantage of using CFC-11 is that it can be handled at only marginally cool room temperatures, whereas CFC-114 20 requires more controlled conditions to avoid evaporation. Upon completion of milling the liquid medium may be removed and recovered under vacuum or heating, resulting in a dry nanoparticulate composition. The dry composition may then be filled into a suitable container and charged with a final propellant. Exemplary final product propellants, which ideally do not contain chlorinated hydrocarbons, include HFA-134a (tetrafluoroethane) 25 and HFA-227 (heptafluoropropane). While non-chlorinated propellants may be preferred for environmental reasons, chlorinated propellants may also be used in this aspect of the invention.

#### 4. Non-Aqueous Pressurized Milling System

In a non-aqueous, pressurized milling system, a non-aqueous liquid medium having a vapor pressure significantly greater than 1 atm at room temperature is used in the milling process to make nanoparticulate drug compositions. If the milling medium is a suitable halogenated hydrocarbon propellant, the resultant dispersion may be filled directly into a suitable pMDI container. Alternately, the milling medium can be removed and recovered under vacuum or heating to yield a dry nanoparticulate composition. This composition can then be filled into an appropriate container and charged with a suitable propellant for use in a pMDI.

10


#### 5. Spray-Dried Powder Aerosol Formulations

Spray drying is a process used to obtain a powder containing nanoparticulate drug particles following particle size reduction of the drug in a liquid medium. In general, spray-drying is used when the liquid medium has a vapor pressure of less than about 1 atm at room temperature. A spray-dryer is a device which allows for liquid evaporation and drug powder collection. A liquid sample, either a solution or suspension, is fed into a spray nozzle. The nozzle generates droplets of the sample within a range of about 20 to about 100  $\mu\text{m}$  in diameter which are then transported by a carrier gas into a drying chamber. The carrier gas temperature is typically between about 80 and about 200°C. The droplets are subjected to rapid liquid evaporation, leaving behind dry particles which are collected in a special reservoir beneath a cyclone apparatus.


If the liquid sample consists of an aqueous dispersion of nanoparticles and surface modifier, the collected product will consist of spherical aggregates of the nanoparticulate drug particles. If the liquid sample consists of an aqueous dispersion of nanoparticles in which an inert diluent material was dissolved (such as lactose or mannitol), the collected product will consist of diluent (e.g., lactose or mannitol) particles which contain embedded nanoparticulate drug particles. The final size of the collected product can be controlled and depends on the concentration of nanoparticulate drug and/or diluent in the liquid sample, as well as the droplet size produced by the spray-dryer.

nozzle. For deep lung delivery it is desirable for the collected product size to be less than about 2  $\mu\text{m}$  in diameter; for delivery to the conducting airways it is desirable for the collected product size to be about 2 to about 6  $\mu\text{m}$  in diameter, and for nasal delivery a collected product size of about 5 to about 100  $\mu\text{m}$  is preferred. Collected products may 5 then be used in conventional DPIs for pulmonary or nasal delivery, dispersed in propellants for use in pMDIs, or the particles may be reconstituted in water for use in nebulizers.

In some instances it may be desirable to add an inert carrier to the spray-dried material to improve the metering properties of the final product. This may 10 especially be the case when the spray dried powder is very small (less than about 5  $\mu\text{m}$ ) or when the intended dose is extremely small, whereby dose metering becomes difficult. In general, such carrier particles (also known as bulking agents) are too large to be delivered to the lung and simply impact the mouth and throat and are swallowed. Such carriers typically consist of sugars such as lactose, mannitol, or trehalose. Other inert materials, 15 including polysaccharides and cellulosics, may also be useful as carriers.



20  
25 Respirable aggregates of nanoparticles mixed with an inert carrier



Respirable diluent particles containing embedded nanoparticles mixed with an inert carrier.

Spray-dried powders containing nanoparticulate drug particles may be used in conventional 30 DPIs, dispersed in propellants for use in pMDIs, or reconstituted in a liquid medium for use with nebulizers.

## 6. Freeze-Dried Nanoparticulate Compositions

For compounds that are denatured or destabilized by heat, such as compounds having a low melting point (*i.e.*, about 70 to about 150°C), or for example, 5 biologics, sublimation is preferred over evaporation to obtain a dry powder nanoparticulate drug composition. This is because sublimation avoids the high process temperatures associated with spray-drying. In addition, sublimation, also known as freeze-drying or lyophilization, can increase the shelf stability of drug compounds, particularly for biological products. Freeze-dried particles can also be reconstituted and 10 used in nebulizers. Aggregates of freeze-dried nanoparticulate drug particles can be blended with either dry powder intermediates or used alone in DPIs and pMDIs for either nasal or pulmonary delivery.

Sublimation involves freezing the product and subjecting the sample to strong vacuum conditions. This allows for the formed ice to be transformed directly from 15 a solid state to a vapor state. Such a process is highly efficient and, therefore, provides greater yields than spray-drying. The resultant freeze-dried product contains drug and modifier(s). The drug is typically present in an aggregated state and can be used for inhalation alone (either pulmonary or nasal), in conjunction with diluent materials (lactose, mannitol, *etc.*), in DPIs or pMDIs, or reconstituted for use in a nebulizer.

20

## C. Methods of Using Nanoparticulate Drug Aerosol Formulations

The aerosols of the present invention, both aqueous and dry powder, are particularly useful in the treatment of respiratory-related illnesses such as asthma, 25 emphysema, respiratory distress syndrome, chronic bronchitis, cystic fibrosis, chronic obstructive pulmonary disease, organ-transplant rejection, tuberculosis and other infections of the lung, fungal infections, respiratory illness associated with acquired immune deficiency syndrome, oncology, and systemic administration of an anti-emetic, analgesic, cardiovascular agent, *etc.* The formulations and method result in improved lung and nasal surface area coverage by the administered drug.

In addition, the aerosols of the invention, both aqueous and dry powder, can be used in a method for diagnostic imaging. Such a method comprises administering to the body of a test subject in need of a diagnostic image an effective contrast-producing amount of the nanoparticulate aerosol diagnostic image contrast composition. Thereafter, 5 at least a portion of the body containing the administered contrast agent is exposed to x-rays or a magnetic field to produce an x-ray or magnetic resonance image pattern corresponding to the presence of the contrast agent. The image pattern can then be visualized.

10 **D. Summary of Advantages of the Compositions and Methods of the Invention**

Using the compositions of the invention, essentially water-insoluble drugs can be delivered to the deep lung. This is either not possible or extremely difficult using aerosol formulations of micronized water-insoluble drugs. Deep lung delivery is necessary for drugs that are intended for systemic administration, because deep lung 15 delivery allows rapid absorption of the drug into the bloodstream via the alveoli, thus enabling rapid onset of action.

The present invention increases the number of drug particles per unit dose and results in distribution of the nanoparticulate drug particles over a larger physiological surface area as compared to the same quantity of delivered micronized drug. For systemic 20 delivery via the pulmonary route, this approach takes maximum advantage of the extensive surface area presented in the alveolar region – thus producing more favorable drug delivery profiles, such as a more complete absorption and rapid onset of action.

Moreover, in contrast to micronized aqueous aerosol dispersions, aqueous dispersions of water-insoluble nanoparticulate drugs can be nebulized ultrasonically. 25 Micronized drug is too large to be delivered efficiently via an ultrasonic nebulizer.

Droplet size determines *in vivo* deposition of a drug, *i.e.*, very small particles, about < 2 microns, are delivered to the alveoli; larger particles, about 2 to about 10 microns, are delivered to the bronchiole region; and for nasal delivery, particles of about 5 to about 100 microns are preferred. Thus, the ability to obtain very small drug 30 particle sizes which can “fit” in a range of droplet sizes allows more effective and more

efficient (*i.e.*, dose uniformity) targeting to the desired delivery region. This is not possible using micronized drug, as the particle size of such drugs is too large to target areas such as the alveolar region of the lung. Moreover, even when micronized drug is incorporated into larger droplet sizes, the resultant aerosol formulation is heterogeneous (*i.e.*, not all droplets contain drug), and does not result in such the rapid and efficient drug delivery enabled by the nanoparticulate aerosol formulations of the invention.

5 The present invention also enables the aqueous aerosol delivery of high doses of drug in an extremely short time period, *i.e.*, 1-2 seconds (1 puff). This is in contrast to the conventional 4-20 min. administration period observed with pulmonary 10 aerosol formulations of micronized drug.

15 Furthermore, the dry aerosol nanoparticulate powders of the present invention are spherical and can be made smaller than micronized material, thereby producing aerosol compositions having better flow and dispersion properties, and capable of being delivered to the deep lung.

20 Finally, the aerosol compositions of the present invention enable rapid nasal delivery. Nasal delivery of such aerosol compositions will be absorbed more rapidly and completely than micronized aerosol compositions before being cleared by the mucociliary mechanism.

20

\* \* \* \* \*

### Drug Particles

25 The nanoparticles of the invention comprise a therapeutic or diagnostic agent, which in the invention are collectively referred to as a "drug." A therapeutic agent can be a pharmaceutical, including biologics such as proteins and peptides, and a diagnostic agent is typically a contrast agent, such as an x-ray contrast agent, or any other type of diagnostic material. The drug exists as a discrete, crystalline phase. The crystalline phase differs from a non-crystalline or amorphous phase which results from precipitation techniques, such as those described in EPO 275,796.

30 The invention can be practiced with a wide variety of drugs. The drug is preferably present in an essentially pure form, is poorly soluble, and is dispersible in at

least one liquid medium. By "poorly soluble" it is meant that the drug has a solubility in the liquid dispersion medium of less than about 10 mg/mL, and preferably of less than about 1 mg/mL.

Suitable drugs include those intended for pulmonary or intranasal delivery.

5 Pulmonary and intranasal delivery are particularly useful for the delivery of proteins and polypeptides which are difficult to deliver by other routes of administration. Such pulmonary or intranasal delivery is effective both for systemic delivery and for localized delivery to treat diseases of the air cavities.

Preferable drug classes include proteins, peptides, bronchodilators,  
10 corticosteroids, elastase inhibitors, analgesics, anti-fungals, cystic-fibrosis therapies, asthma therapies, emphysema therapies, respiratory distress syndrome therapies, chronic bronchitis therapies, chronic obstructive pulmonary disease therapies, organ-transplant rejection therapies, therapies for tuberculosis and other infections of the lung, fungal infection therapies, and respiratory illness therapies associated with acquired immune  
15 deficiency syndrome, oncology therapies, systemic administration of anti-emetics, analgesics, cardiovascular agents, etc.

The drug can be selected from a variety of known classes of drugs, including, for example, analgesics, anti-inflammatory agents, anthelmintics, anti-arrhythmic agents, antibiotics (including penicillins), anticoagulants, antidepressants,  
20 antidiabetic agents, antiepileptics, antihistamines, antihypertensive agents, antimuscarinic agents, antimycobacterial agents, antineoplastic agents, immunosuppressants, antithyroid agents, antiviral agents, anxiolytic sedatives (hypnotics and neuroleptics), astringents, beta-adrenoceptor blocking agents, blood products and substitutes, cardiac inotropic agents, contrast media, corticosteroids, cough suppressants (expectorants and mucolytics),  
25 diagnostic agents, diagnostic imaging agents, diuretics, dopaminergics (antiparkinsonian agents), haemostatics, immunological agents, lipid regulating agents, muscle relaxants, parasympathomimetics, parathyroid calcitonin and biphosphonates, prostaglandins, radio-pharmaceuticals, sex hormones (including steroids), anti-allergic agents, stimulants and anoretics, sympathomimetics, thyroid agents, vasodilators and xanthines.

A description of these classes of drugs and a listing of species within each class can be found in Martindale, *The Extra Pharmacopoeia*, Twenty-ninth Edition (The Pharmaceutical Press, London, 1989), specifically incorporated by reference. The drugs are commercially available and/or can be prepared by techniques known in the art.

5 Preferred contrast agents are taught in the '684 patent, which is specifically incorporated by reference. Suitable diagnostic agents are also disclosed in U.S. Patent No. 5,260,478; U.S. Patent No. 5,264,610; U.S. Patent No. 5,322,679; and U.S. Patent No. 5,300,739, all specifically incorporated by reference.

10 **Surface Modifiers**

Suitable surface modifiers can preferably be selected from known organic and inorganic pharmaceutical excipients. Such excipients include various polymers, low molecular weight oligomers, natural products, and surfactants. Preferred surface modifiers include nonionic and ionic surfactants. Two or more surface modifiers can be 15 used in combination.

Representative examples of surface modifiers include cetyl pyridinium chloride, gelatin, casein, lecithin (phosphatides), dextran, glycerol, gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, 20 polyoxyethylene alkyl ethers (e.g., macrogol ethers such as cetomacrogol 1000), polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters (e.g., the commercially available Tweens® such as e.g., Tween 20® and Tween 80® (ICI Specialty Chemicals)); polyethylene glycols (e.g., Carbowaxs 3350® and 1450®, and Carbopol 934® (Union Carbide)), dodecyl trimethyl ammonium bromide, polyoxyethylene stearates, 25 colloidal silicon dioxide, phosphates, sodium dodecylsulfate, carboxymethylcellulose calcium, hydroxypropyl cellulose (HPC, HPC-SL, and HPC-L), hydroxypropyl methylcellulose (HPMC), carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethyl-cellulose phthalate, noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, 30 polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), 4-(1,1,3,3-tetramethylbutyl)-

phenol polymer with ethylene oxide and formaldehyde (also known as tyloxapol, superione, and triton), poloxamers (e.g., Pluronics F68® and F108®, which are block copolymers of ethylene oxide and propylene oxide); poloxamines (e.g., Tetronic 908®, also known as Poloxamine 908®, which is a tetrafunctional block copolymer derived from sequential addition of propylene oxide and ethylene oxide to ethylenediamine (BASF Wyandotte Corporation, Parsippany, N.J.)); a charged phospholipid such as dimyristoyl phosphatidyl glycerol, dioctylsulfosuccinate (DOSS); Tetronic 1508® (T-1508) (BASF Wyandotte Corporation ), dialkylesters of sodium sulfosuccinic acid (e.g., Aerosol OT®, which is a dioctyl ester of sodium sulfosuccinic acid (American Cyanamid)); Duponol P®, which is a sodium lauryl sulfate (DuPont); Tritons X-200®, which is an alkyl aryl polyether sulfonate (Rohm and Haas); Crodestas F-110®, which is a mixture of sucrose stearate and sucrose distearate (Croda Inc.); p-isobutylphenoxyxypoly-(glycidol), also known as Olin-LOG® or Surfactant 10-G®(Olin Chemicals, Stamford, CT); Crodestas SL-40® (Croda, Inc.); and SA9OHCO, which is C<sub>18</sub>H<sub>37</sub>CH<sub>2</sub>(CON(CH<sub>3</sub>)-CH<sub>2</sub>(CHOH)<sub>4</sub>(CH<sub>2</sub>OH)<sub>2</sub> (Eastman Kodak Co.); decanoyl-N-methylglucamide; n-decyl β-D-glucopyranoside; n-decyl β-D-maltopyranoside; n-dodecyl β-D-glucopyranoside; n-dodecyl β-D-maltoside; heptanoyl-N-methylglucamide; n-heptyl-β-D-glucopyranoside; n-heptyl β-D-thioglucoside; n-hexyl β-D-glucopyranoside; nonanoyl-N-methylglucamide; n-nonyl β-D-glucopyranoside; octanoyl-N-methylglucamide; n-octyl-β-D-glucopyranoside; octyl β-D-thioglucopyranoside; and the like. Tyloxapol is a particularly preferred surface modifier for the pulmonary or intranasal delivery of steroids, even more so for nebulization therapies.

Most of these surface modifiers are known pharmaceutical excipients and are described in detail in the *Handbook of Pharmaceutical Excipients*, published jointly by the American Pharmaceutical Association and The Pharmaceutical Society of Great Britain (The Pharmaceutical Press, 1986), specifically incorporated by reference. The surface modifiers are commercially available and/or can be prepared by techniques known in the art.

Ratios

The relative amount of drug and surface modifier can vary widely and the optimal amount of the surface modifier can depend upon, for example, the particular drug and surface modifier selected, the critical micelle concentration of the surface modifier if it forms micelles, the hydrophilic-lipophilic-balance (HLB) of the surface modifier, the melting point of the surface modifier, the water solubility of the surface modifier and/or drug, the surface tension of water solutions of the surface modifier, *etc.*

In the present invention, the optimal ratio of drug to surface modifier is about 1% to about 99% drug, more preferably about 30% to about 90% drug.

10

\* \* \* \*

The following examples are given to illustrate the present invention. It should be understood, however, that the invention is not to be limited to the specific 15 conditions or details described in these examples.

Example 1

The purpose of this example was to demonstrate the ability to aerosolize a concentrated nanoparticulate dispersion in an ultrasonic nebulizer which incorporates a 20 fine mesh screen in its design. An additional purpose of this example was to demonstrate that a therapeutic quantity of a concentrated nanoparticulate corticosteroid can be aerosolized in a very short period of time; e.g., two seconds or less.

Two different nanoparticulate dispersions of beclomethasone dipropionate (BDP) (1.25% and 10% BDP) were aerosolized using an ultrasonic nebulizer (Omron NE-25 U03 MicroAir®). The nebulizer generated droplets on a piezoelectric crystal and extruded them through a screen which contains ultrafine laser-drilled holes, producing an aerosol which has a very narrow particle size distribution in the range of approximately 1-5  $\mu\text{m}$ . The device was connected to an Andersen cascade impactor with a flow rate at 28.3 liters per minute. For each formulation, the nebulizer was actuated for two seconds using a 30 programmable timer. The actuation time roughly corresponds to one inhalation cycle

with a pMDI. After actuation, each stage of the impactor was analyzed for drug deposition by HPLC analysis.

The data indicate that substantial quantities of drug substance were found on stages 3-6 of the cascade impactor, corresponding to aerodynamic droplet sizes of about 0.7 to 4.7  $\mu\text{m}$ . The total amount of drug in the respirable droplet size range for deep lung delivery (*i.e.*, particles less than about 2 microns; Stages 5, 6, and 7) was 11.72  $\mu\text{g}$  for the 1.25% BDP (w/w) dispersion and 18.36  $\mu\text{g}$  for the 10% BDP (w/w) dispersion. The total amount of drug in the respirable droplet size range for upper pulmonary delivery (*i.e.* particles about 2 to 5 microns; Stages 2, 3, 4, and 5) was 17.26  $\mu\text{g}$  for the 1.25% BDP dispersion and 178.40  $\mu\text{g}$  for the 10% BDP dispersion.

One advantage provided by nanoparticulate formulations is that the drug particles are small enough to pass through the finer mesh channels of the nebulizer. In contrast, conventional micronized drug material would be expected to clog the orifices in the screen. Cascade impactor data from an *in vitro* deposition study of a nanoparticulate BDP dispersion aerosolized by an Omron NE-U03 Ultrasonic Nebulizer are summarized in Table I below:

**TABLE I**

Observed <i>In-Vitro</i> Deposition Pattern of an Aerosolized Nanoparticulate BDP Dispersion			
Deposition Site/ Impactor Area	Droplet Size Range ( $\mu\text{m}$ ) <sup>a</sup>	1.25% BDP <sup>b</sup> ( $\mu\text{g}$ Collected)	10% BDP <sup>c</sup> ( $\mu\text{g}$ Collected)
Stage 0	9.0 - 10.0	4.76	19.30
Stage 1	5.8 - 9.0	1.95	37.50
Stage 2	4.7 - 5.8	0.75	42.00
Stage 3	3.3 - 4.7	1.73	79.40
Stage 4	2.1 - 3.3	5.97	45.20
Stage 5	1.1 - 2.1	8.81	11.80
Stage 6	0.7 - 1.1	2.09	3.59
Stage 7	0.4 - 0.7	0.82	2.97
After Filter	<0.4	2.25	18.70
<b>TOTAL</b>		29.13	126.46
Collar	N/A	0.00	N/A
Induction Port	N/A	4.10	22.40
Adapter	N/A	N/A	N/A
Tube	N/A	N/A	10.98

<sup>a</sup>All results based on 2 second actuation with the Omron NE-U03.

<sup>b</sup>Particle Size of concentrate BDP 1.25% (w/w): mean of 171 nm, 90% < 234 nm, standard deviation 30 nm

<sup>c</sup>Particle Size of concentrate BDP 10% (w/w): mean of 94 nm, 90% < 130 nm, standard deviation 30 nm

The results, which are graphically depicted in Figure 1, show substantial deposition of drug at Stages 2, 3, 4, and 5. This corresponds to delivery to conducting airways. Most of the drug substance is found in droplets of about 2 to about 6  $\mu\text{m}$ , which are ideal for delivery to the bronchiole region.

### Example 2

The purpose of this example was to demonstrate aerosolization of a nanoparticulate dispersion using a using a jet nebulizer (Circulaire<sup>®</sup>, Westmed, Inc., Tucson, AZ), which can produce aqueous droplets in the size range of 0.5-2.0  $\mu\text{m}$ . Such droplet sizes are suitable for delivery to the alveolar region of the lung, *i.e.*, deep lung delivery.

A nanoparticulate dispersion of BDP was prepared by wet milling micronized drug substance in an aqueous tyloxapol surface modifier solution until a satisfactory particle size distribution had been obtained. The formulation was evaluated

by light scattering methods (Microtrac UPA, Leeds & Northrup) and was found to have a mean particle size of 139 nm, with 90% of the particles being less than 220 nm (volume statistics).

5 The delivery performance of the BDP/surface modifier dispersion in a jet nebulizer was evaluated as follows: Approximately 3.5 ml of the BDP/surface modifier dispersion (2 mg/ml) was added to the nebulizer bowl, and the nebulizer mouthpiece was connected to the throat of a cascade impactor apparatus with an airtight seal. The nebulizer and cascade impactor were then operated under suitable pressure and flow conditions for approximately 4 minutes using a 4 seconds on/4 seconds off cycle. Upon 10 completion of the nebulization, each section of the apparatus was rinsed with acetonitrile and the washings diluted volumetrically.

The quantity of drug substance present in each section of the apparatus was determined by high performance liquid chromatography.

15 **Results**

Analysis of the chromatograms showed that relatively little drug substance was deposited in the higher regions of the cascade impactor apparatus, while substantial quantities of material appeared on stages 5-7, as well as on the exit filter. In Experiment 1, approximately 92% of the emitted dose (ex-device) was contained in droplets < 2.1  $\mu\text{m}$  20 in diameter; in Experiment 2 the value was 86%. The results indicate that substantial quantities of drug substance were found on cascade impactor stages 5, 6, and 7, corresponding to droplet sizes of about 0.43 to about 2.1 microns. The smallest drug particle size normally accessible by conventional micronization methods for raw materials is about 2 to 3 microns, which is clearly larger than the droplets generated by this jet 25 nebulizer. Detailed results of the cascade impactor study are presented Table II below, and graphically in Figure 2.

**TABLE II**  
**Observed *In Vitro* Deposition Pattern of a Nanoparticulate BDP Suspension**

Deposition Site	Droplet Size Range ( $\mu\text{m}$ )	Experiment 1 <sup>a</sup>	Experiment 2 <sup>a</sup>
Throat		33.13	36.00
Preselector, Stage 0	> 9.0	17.64	65.27
Stages 1 and 2	4.7 – 9.0	19.90	80.69
Stage 3	3.3 – 4.7	8.76	55.59
Stage 4	2.1 – 3.3	2.13	17.90
Stage 5	1.1 – 2.1	122.41	336.16
Stage 6	0.65 – 1.1	354.20	580.20
Stage 7	0.43 – 0.65	286.42	376.11
filter	< 0.43	297.60	297.15
<b>TOTAL</b>		<b>1142.19</b>	<b>1845.07</b>

<sup>a</sup> $\mu\text{g}$  of BDP Collected

5 In contrast to Example 1, which used an ultrasonic nebulizer (Omron NE-U03 MicroAir<sup>®</sup>) that generates droplets in the range of 2-6  $\mu\text{m}$ , this example used a jet nebulizer that generates droplets in the range of < 2  $\mu\text{m}$ . The successful deposition of aerosol drug particles at Stages 6 and 7 demonstrates the effectiveness of using such compositions for deep lung delivery.

10

### Example 3

The purpose of this example was to demonstrate the preparation of a nanoparticulate dry powder for use in a DPI.

15 40.0% (w/w) naproxen, 4.00% (w/w) PVP K29/30 (a surface modifier), and 56.0% (w/w) deionized water were milled with 500  $\mu\text{m}$  SDy-20 polymeric media for 7.5 hours to achieve a mean particle size of 254 nm, with 90% of the particles having a size of less than 335 nm. The material was diluted to 20% (w/w) naproxen and further milled with 50  $\mu\text{m}$  SDy-20 media for a period of 6 hours to yield a mean particle size of 155 nm, with 90% of the particles having a particle size of less than 212 nm. The 20 nanoparticulate dispersion was then diluted to 2% (w/w) naproxen with sufficient quantities of Sterile Water for Injection. The suspension was then spray-dried using a Yamato GB-22 operating with the following parameters:

5	Inlet Temp.:	130°C
	Outlet Temp.:	71 - 76°C
	Drying Air:	0.37 m <sup>3</sup> /min.
	Atom. Air:	2 M Pa
	Pump Speed:	ca. 8.4 mL/min.

The resultant nanoparticulate powder possessed a MMAD of 1.67  $\mu$ m, with 90% of the particles having a MMAD of less than 2.43  $\mu$ m, as determined by a time-of-flight particle sizing instrument. *See Figure 3*, which shows the volume distribution by the aerodynamic diameter of the spray-dried naproxen aerosol. Thus, all particles fell 10 within the respirable size range required for pulmonary deposition. Additionally, greater than 50 percent of the particle population fell within the size required for peripheral lung deposition (alveolar, < 2  $\mu$ m).

Interestingly, the spray-dried drug particles also demonstrated a spherical shape, which will improve the flow properties of the powder (as compared to prior 15 micronized spray-dried powder formulations). The electron micrograph of Figure 4 clearly shows the overall uniformity of size and the spherical nature of the particles. In addition, the exterior surface of the drug particle, which is composed of the polymeric stabilizer, may have advantages in limiting moisture uptake upon storage.

Lastly, to demonstrate that these spray-dried particles are constructed of 20 aggregates of the original nanoparticulate drug, reconstitution in a liquid medium resulted in the return to the original nanoparticulate dispersion, with a mean particle size of 184 nm, and 90 % of the particles having a size of less than 255 nm.

#### Example 4

25 The purpose of this example was to further demonstrate the ability to influence the aerodynamic size of the spray-dried nanoparticulate composition by using a different concentration of nanoparticulate drug dispersion.

The concentration of naproxen and surface modifier (PVP K29/30) was the same as in Example 5, except that the composition was diluted with Sterile Water for 30 Injection to achieve a 5 % (w/w) naproxen suspension. The spray-drier used was the Yamato GB-22, with the same operating parameters used in Example 4.

The resultant powder was composed of nanoparticulate aggregates with a MMAD of 2.91  $\mu\text{m}$ , with 90% of the drug particles having a MMAD of less than 4.65  $\mu\text{m}$ . This material is within the desired range for inhaled pulmonary deposition and may be more suitable for central airway targeting, *i.e.*, within a range of 2 to 6  $\mu\text{m}$ . *See Figure 5*, which shows the volume distribution by the aerodynamic diameter of the spray-dried naproxen aerosol.

#### Example 5

The purpose of this example was to produce a spray-dried nanoparticulate powder for aerosol administration.

20.0% (w/w) triamcinolone acetonide (TA), 2.00% (w/w) HPC-SL (a surface modifier), 0.01% (w/w) benzalkonium chloride (BKC), and 76.9% (w/w) deionized water was milled in the presence of 500  $\mu\text{m}$  SDy-20 polymeric media for approximately one hour. The final drug mean particle size was 169 nm, with 90 % of the drug particles having a size of less than 259 nm. The nanoparticulate drug dispersion was then diluted to 10% (w/w) TA with a 0.01 % BKC solution. The dispersion was then spray-dried using a Buchi B-191 spray-drier at the following settings:

20	Inlet Temp.:	130°C
	Outlet Temp.:	76°C
	Aspirator setting:	90% capacity
	Product feed:	18% capacity

The resultant nanoparticulate powder possessed aggregates of nanoparticulate TA particles with a MMAD of 5.54  $\mu\text{m}$ , and 90 % of the TA particles had a MMAD of less than 9.08  $\mu\text{m}$  via a time-of-flight measuring system. Thus, 50 percent of the particles fall within the respirable range for central airway (bronchiole deposition). *See Figure 6*, which shows the volume distribution by the aerodynamic diameter of the spray-dried TA aerosol. In addition, the TA powder was of spherical shape as compared to the jet-milled drug, thus affording improved flow properties. Lastly, the powder redisperses in liquid medium to achieve well-dispersed nanoparticles of drug at a mean particle size of 182 nm.

### Example 6

The purpose of this example was to produce a spray-dried nanoparticulate drug/surface modifier powder for aerosol administration, wherein the composition lacks a diluent. In addition, this example compares the deposition of the nanoparticulate powder with the deposition of a micronized drug substance in a dry-powder delivery device. 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100 105 110 115 120 125 130 135 140 145 150 155 160 165 170 175 180 185 190 195 200 205 210 215 220 225 230 235 240 245 250 255 260 265 270 275 280 285 290 295 300 305 310 315 320 325 330 335 340 345 350 355 360 365 370 375 380 385 390 395 400 405 410 415 420 425 430 435 440 445 450 455 460 465 470 475 480 485 490 495 500 505 510 515 520 525 530 535 540 545 550 555 560 565 570 575 580 585 590 595 600 605 610 615 620 625 630 635 640 645 650 655 660 665 670 675 680 685 690 695 700 705 710 715 720 725 730 735 740 745 750 755 760 765 770 775 780 785 790 795 800 805 810 815 820 825 830 835 840 845 850 855 860 865 870 875 880 885 890 895 900 905 910 915 920 925 930 935 940 945 950 955 960 965 970 975 980 985 990 995 1000 1005 1010 1015 1020 1025 1030 1035 1040 1045 1050 1055 1060 1065 1070 1075 1080 1085 1090 1095 1100 1105 1110 1115 1120 1125 1130 1135 1140 1145 1150 1155 1160 1165 1170 1175 1180 1185 1190 1195 1200 1205 1210 1215 1220 1225 1230 1235 1240 1245 1250 1255 1260 1265 1270 1275 1280 1285 1290 1295 1300 1305 1310 1315 1320 1325 1330 1335 1340 1345 1350 1355 1360 1365 1370 1375 1380 1385 1390 1395 1400 1405 1410 1415 1420 1425 1430 1435 1440 1445 1450 1455 1460 1465 1470 1475 1480 1485 1490 1495 1500 1505 1510 1515 1520 1525 1530 1535 1540 1545 1550 1555 1560 1565 1570 1575 1580 1585 1590 1595 1600 1605 1610 1615 1620 1625 1630 1635 1640 1645 1650 1655 1660 1665 1670 1675 1680 1685 1690 1695 1700 1705 1710 1715 1720 1725 1730 1735 1740 1745 1750 1755 1760 1765 1770 1775 1780 1785 1790 1795 1800 1805 1810 1815 1820 1825 1830 1835 1840 1845 1850 1855 1860 1865 1870 1875 1880 1885 1890 1895 1900 1905 1910 1915 1920 1925 1930 1935 1940 1945 1950 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000 2005 2010 2015 2020 2025 2030 2035 2040 2045 2050 2055 2060 2065 2070 2075 2080 2085 2090 2095 2100 2105 2110 2115 2120 2125 2130 2135 2140 2145 2150 2155 2160 2165 2170 2175 2180 2185 2190 2195 2200 2205 2210 2215 2220 2225 2230 2235 2240 2245 2250 2255 2260 2265 2270 2275 2280 2285 2290 2295 2300 2305 2310 2315 2320 2325 2330 2335 2340 2345 2350 2355 2360 2365 2370 2375 2380 2385 2390 2395 2400 2405 2410 2415 2420 2425 2430 2435 2440 2445 2450 2455 2460 2465 2470 2475 2480 2485 2490 2495 2500 2505 2510 2515 2520 2525 2530 2535 2540 2545 2550 2555 2560 2565 2570 2575 2580 2585 2590 2595 2600 2605 2610 2615 2620 2625 2630 2635 2640 2645 2650 2655 2660 2665 2670 2675 2680 2685 2690 2695 2700 2705 2710 2715 2720 2725 2730 2735 2740 2745 2750 2755 2760 2765 2770 2775 2780 2785 2790 2795 2800 2805 2810 2815 2820 2825 2830 2835 2840 2845 2850 2855 2860 2865 2870 2875 2880 2885 2890 2895 2900 2905 2910 2915 2920 2925 2930 2935 2940 2945 2950 2955 2960 2965 2970 2975 2980 2985 2990 2995 3000 3005 3010 3015 3020 3025 3030 3035 3040 3045 3050 3055 3060 3065 3070 3075 3080 3085 3090 3095 3100 3105 3110 3115 3120 3125 3130 3135 3140 3145 3150 3155 3160 3165 3170 3175 3180 3185 3190 3195 3200 3205 3210 3215 3220 3225 3230 3235 3240 3245 3250 3255 3260 3265 3270 3275 3280 3285 3290 3295 3300 3305 3310 3315 3320 3325 3330 3335 3340 3345 3350 3355 3360 3365 3370 3375 3380 3385 3390 3395 3400 3405 3410 3415 3420 3425 3430 3435 3440 3445 3450 3455 3460 3465 3470 3475 3480 3485 3490 3495 3500 3505 3510 3515 3520 3525 3530 3535 3540 3545 3550 3555 3560 3565 3570 3575 3580 3585 3590 3595 3600 3605 3610 3615 3620 3625 3630 3635 3640 3645 3650 3655 3660 3665 3670 3675 3680 3685 3690 3695 3700 3705 3710 3715 3720 3725 3730 3735 3740 3745 3750 3755 3760 3765 3770 3775 3780 3785 3790 3795 3800 3805 3810 3815 3820 3825 3830 3835 3840 3845 3850 3855 3860 3865 3870 3875 3880 3885 3890 3895 3900 3905 3910 3915 3920 3925 3930 3935 3940 3945 3950 3955 3960 3965 3970 3975 3980 3985 3990 3995 4000 4005 4010 4015 4020 4025 4030 4035 4040 4045 4050 4055 4060 4065 4070 4075 4080 4085 4090 4095 4100 4105 4110 4115 4120 4125 4130 4135 4140 4145 4150 4155 4160 4165 4170 4175 4180 4185 4190 4195 4200 4205 4210 4215 4220 4225 4230 4235 4240 4245 4250 4255 4260 4265 4270 4275 4280 4285 4290 4295 4300 4305 4310 4315 4320 4325 4330 4335 4340 4345 4350 4355 4360 4365 4370 4375 4380 4385 4390 4395 4400 4405 4410 4415 4420 4425 4430 4435 4440 4445 4450 4455 4460 4465 4470 4475 4480 4485 4490 4495 4500 4505 4510 4515 4520 4525 4530 4535 4540 4545 4550 4555 4560 4565 4570 4575 4580 4585 4590 4595 4600 4605 4610 4615 4620 4625 4630 4635 4640 4645 4650 4655 4660 4665 4670 4675 4680 4685 4690 4695 4700 4705 4710 4715 4720 4725 4730 4735 4740 4745 4750 4755 4760 4765 4770 4775 4780 4785 4790 4795 4800 4805 4810 4815 4820 4825 4830 4835 4840 4845 4850 4855 4860 4865 4870 4875 4880 4885 4890 4895 4900 4905 4910 4915 4920 4925 4930 4935 4940 4945 4950 4955 4960 4965 4970 4975 4980 4985 4990 4995 5000 5005 5010 5015 5020 5025 5030 5035 5040 5045 5050 5055 5060 5065 5070 5075 5080 5085 5090 5095 5100 5105 5110 5115 5120 5125 5130 5135 5140 5145 5150 5155 5160 5165 5170 5175 5180 5185 5190 5195 5200 5205 5210 5215 5220 5225 5230 5235 5240 5245 5250 5255 5260 5265 5270 5275 5280 5285 5290 5295 5300 5305 5310 5315 5320 5325 5330 5335 5340 5345 5350 5355 5360 5365 5370 5375 5380 5385 5390 5395 5400 5405 5410 5415 5420 5425 5430 5435 5440 5445 5450 5455 5460 5465 5470 5475 5480 5485 5490 5495 5500 5505 5510 5515 5520 5525 5530 5535 5540 5545 5550 5555 5560 5565 5570 5575 5580 5585 5590 5595 5600 5605 5610 5615 5620 5625 5630 5635 5640 5645 5650 5655 5660 5665 5670 5675 5680 5685 5690 5695 5700 5705 5710 5715 5720 5725 5730 5735 5740 5745 5750 5755 5760 5765 5770 5775 5780 5785 5790 5795 5800 5805 5810 5815 5820 5825 5830 5835 5840 5845 5850 5855 5860 5865 5870 5875 5880 5885 5890 5895 5900 5905 5910 5915 5920 5925 5930 5935 5940 5945 5950 5955 5960 5965 5970 5975 5980 5985 5990 5995 6000 6005 6010 6015 6020 6025 6030 6035 6040 6045 6050 6055 6060 6065 6070 6075 6080 6085 6090 6095 6100 6105 6110 6115 6120 6125 6130 6135 6140 6145 6150 6155 6160 6165 6170 6175 6180 6185 6190 6195 6200 6205 6210 6215 6220 6225 6230 6235 6240 6245 6250 6255 6260 6265 6270 6275 6280 6285 6290 6295 6300 6305 6310 6315 6320 6325 6330 6335 6340 6345 6350 6355 6360 6365 6370 6375 6380 6385 6390 6395 6400 6405 6410 6415 6420 6425 6430 6435 6440 6445 6450 6455 6460 6465 6470 6475 6480 6485 6490 6495 6500 6505 6510 6515 6520 6525 6530 6535 6540 6545 6550 6555 6560 6565 6570 6575 6580 6585 6590 6595 6600 6605 6610 6615 6620 6625 6630 6635 6640 6645 6650 6655 6660 6665 6670 6675 6680 6685 6690 6695 6700 6705 6710 6715 6720 6725 6730 6735 6740 6745 6750 6755 6760 6765 6770 6775 6780 6785 6790 6795 6800 6805 6810 6815 6820 6825 6830 6835 6840 6845 6850 6855 6860 6865 6870 6875 6880 6885 6890 6895 6900 6905 6910 6915 6920 6925 6930 6935 6940 6945 6950 6955 6960 6965 6970 6975 6980 6985 6990 6995 7000 7005 7010 7015 7020 7025 7030 7035 7040 7045 7050 7055 7060 7065 7070 7075 7080 7085 7090 7095 7100 7105 7110 7115 7120 7125 7130 7135 7140 7145 7150 7155 7160 7165 7170 7175 7180 7185 7190 7195 7200 7205 7210 7215 7220 7225 7230 7235 7240 7245 7250 7255 7260 7265 7270 7275 7280 7285 7290 7295 7300 7305 7310 7315 7320 7325 7330 7335 7340 7345 7350 7355 7360 7365 7370 7375 7380 7385 7390 7395 7400 7405 7410 7415 7420 7425 7430 7435 7440 7445 7450 7455 7460 7465 7470 7475 7480 7485 7490 7495 7500 7505 7510 7515 7520 7525 7530 7535 7540 7545 7550 7555 7560 7565 7570 7575 7580 7585 7590 7595 7600 7605 7610 7615 7620 7625 7630 7635 7640 7645 7650 7655 7660 7665 7670 7675 7680 7685 7690 7695 7700 7705 7710 7715 7720 7725 7730 7735 7740 7745 7750 7755 7760 7765 7770 7775 7780 7785 7790 7795 7800 7805 7810 7815 7820 7825 7830 7835 7840 7845 7850 7855 7860 7865 7870 7875 7880 7885 7890 7895 7900 7905 7910 7915 7920 7925 7930 7935 7940 7945 7950 7955 7960 7965 7970 7975 7980 7985 7990 7995 8000 8005 8010 8015 8020 8025 8030 8035 8040 8045 8050 8055 8060 8065 8070 8075 8080 8085 8090 8095 8100 8105 8110 8115 8120 8125 8130 8135 8140 8145 8150 8155 8160 8165 8170 8175 8180 8185 8190 8195 8200 8205 8210 8215 8220 8225 8230 8235 8240 8245 8250 8255 8260 8265 8270 8275 8280 8285 8290 8295 8300 8305 8310 8315 8320 8325 8330 8335 8340 8345 8350 8355 8360 8365 8370 8375 8380 8385 8390 8395 8400 8405 8410 8415 8420 8425 8430 8435 8440 8445 8450 8455 8460 8465 8470 8475 8480 8485 8490 8495 8500 8505 8510 8515 8520 8525 8530 8535 8540 8545 8550 8555 8560 8565 8570 8575 8580 8585 8590 8595 8600 8605 8610 8615 8620 8625 8630 8635 8640 8645 8650 8655 8660 8665 8670 8675 8680 8685 8690 8695 8700 8705 8710 8715 8720 8725 8730 8735 8740 8745 8750 8755 8760 8765 8770 8775 8780 8785 8790 8795 8800 8805 8810 8815 8820 8825 8830 8835 8840 8845 8850 8855 8860 8865 8870 8875 8880 8885 8890 8895 8900 8905 8910 8915 8920 8925 8930 8935 8940 8945 8950 8955 8960 8965 8970 8975 8980 8985 8990 8995 9000 9005 9010 9015 9020 9025 9030 9035 9040 9045 9050 9055 9060 9065 9070 9075 9080 9085 9090 9095 9100 9105 9110 9115 9120 9125 9130 9135 9140 9145 9150 9155 9160 9165 9170 9175 9180 9185 9190 9195 9200 9205 9210 9215 9220 9225 9230 9235 9240 9245 9250 9255 9260 9265 9270 9275 9280 9285 9290 9295 9300 9305 9310 9315 9320 9325 9330 9335 9340 9345 9350 9355 9360 9365 9370 9375 9380 9385 9390 9395 9400 9405 9410 9415 9420 9425 9430 9435 9440 9445 9450 9455 9460 9465 9470 9475 9480 9485 9490 9495 9500 9505 9510 9515 9520 9525 9530 9535 9540 9545 9550 9555 9560 9565 9570 9575 9580 9585 9590 9595 9600 9605 9610 9615 9620 9625 9630 9635 9640 9645 9650 9655 9660 9665 9670 9675 9680 9685 9690 9695 9700 9705 9710 9715 9720 9725 9730 9735 9740 9745 9750 9755 9760 9765 9770 9775 9780 9785 9790 9795 9800 9805 9810 9815 9820 9825 9830 9835 9840 9845 9850 9855 9860 9865 9870 9875 9880 9885 9890 9895 9900 9905 9910 9915 9920 9925 9930 9935 9940 9945 9950 9955 9960 9965 9970 9975 9980 9985 9990 9995 9999 10000 10005 10010 10015 10020 10025 10030 10035 10040 10045 10050 10055 10060 10065 10070 10075 10080 10085 10090 10095 10099 10100 10101 10102 10103 10104 10105 10106 10107 10108 10109 10110 10111 10112 10113 10114 10115 10116 10117 10118 10119 10120 10121 10122 10123 10124 10125 10126 10127 10128 10129 10130 10131 10132 10133 10134 10135 10136 10137 10138 10139 10140 10141 10142 10143 10144 10145 10146 10147 10148 10149 10150 10151 10152 10153 10154 10155 10156 10157 10158 10159 10160 10161 10162 10163 10164 10165 10166 10167 10168 10169 10170 10171 10172 10173 10174 10175 10176 10177 10178 10179 10180 10181 10182 10183 10184 10185 10186 10187 10188 10189 10190 10191 10192 10193 10194 10195 10196 10197 10198 10199 10200 10201 10202 10203 10204 10205 10206 10207 10208 10209 10210 10211 10212 10213 10214 10215 10216 10217 10218 10219 10220 10221 10222 10223 10224 10225 10226 10227 10228 10229 10230 10231 10232 10233 10234 10235 10236 10237 10238 10239 10240 10241 10242 10243 10244 10245 10246 10247 10248 10249 10250 10251 10252 10253 10254 10255 10256 10257 10258 10259 10260 10261 10262 10263 10264 10265 10266 10267 10268 10269 10270 10271 10272 10273 10274 10275 10276 10277 10278 10279 10280 10281 10282 10283 10284 10285 10286 10287 10288 10289 10290 10291 10292 10293 10294 10295 10296 10297 10298 10299 10300 10301 10302 10303 10304 10305 10306 10307 10308 10309 10310 10311 10312 10313 10314 10315 10316 10317 10318 10319 10320 10321 10322 10323 10324 10325 10326 10327 10328 10329 10330 10331 10332 10333 10334 10335 10336 10337 10338 10339 10340 10341 10342 10343 10344 10345 10346 10347 10348 10349 10350 10351 10352 10353 10354 10355 10356 10357 10358 10359 10360 10361 10362 10363 10364 10365 10366 10367 10368 10369 10370 10371 10372 10373 10374 10375 10376 10377 10378 10379 10380 10381 10382 10383 10384 10385 10386 10387 10388 10389 10390 10391 10392 10393 10394 10395 10396 10397 10398 10399 10400 10401 10402 10403 10404 10405 10406 10407 10408 10409 10410 10411 10412 10413 10414 10415 10416 10417 10418 10419 10420 10421 10422 10423 10424 10425 10426 10427 10428 10429 10430 10431 10432 10433 10434 10435 10436 10437 10438 10439 10440 10441 10442 10443 10444 10445 10446 10447 10448 10449 10450 10451 10452 10453 10454 10455 10456 10457 10458 10459 10460 10461 10462 10463 10464 10465 10466 10467 10468 10469 10470 10471 10472 10473 10474 10475 10476 10477 10478 10479 10480 10481 10482 10483 10484 10485 10486 10487 10488 10489 10490 10491 10492 10493 10494 10495 10496 10

Inlet Temperature: 125°C  
 Drying Air: 0.40 m<sup>3</sup>/minute  
 Atomizing Air: 0.2 MPa  
 Outlet Temperature: 60-61°C

The resultant nanoparticulate aggregates possessed a MMAD of 1.35  $\mu\text{m}$ , with 90% of the particles having a MMAD of less than 2.24  $\mu\text{m}$ , as measured by time-of-flight methodology.

20 A final powder blend was made, composed of 4% (w/w) nanoparticulate budesonide/surface modifier (3.2% (w/w) drug) and 96% lactose. The mixing was carried out using a Patterson-Kelley V-Blender with Lexan shell. The same procedure was followed for micronized budesonide at 3.4% (w/w) drug (Sicor, Via Terrazano 77, Italy).

25 Each drug powder – the nanoparticulate and the micronized – was then loaded into a Clickhaler™ (ML Laboratories plc, England), having a 1.5 mm<sup>3</sup> dosing chamber. Each unit was evaluated using an Andersen cascade impactor operating at approximately 60 liters per minute. Five actuations were delivered to the impactor and the unit was then disassembled and the collection plates analyzed via HPLC. This was performed in triplicate. The data as percent of emitted dose from the DPI is shown below

30 in Table III.

TABLE III

<i>In vitro</i> Deposition of Nanoparticulate Budesonide vs Micronized Budesonide in a DPI*			
Impactor Region	Aerodynamic Particle Size Range ( $\mu\text{m}$ )	Nanoparticulate Budesonide	Micronized Budesonide
Stage 0	5.9 - 10.0	14.1	16.7
Stage 1	4.1 - 5.9	1.03	5.31
Stage 2	3.2 - 4.1	3.09	4.76
Stage 3	2.1 - 3.2	14.9	7.74
Stage 4	1.4 - 2.1	26.7	5.73
Stage 5	0.62 - 1.4	12.1	3.48
Stage 6	0.35 - 0.62	2.22	N/D
Stage 7	0.15 - 0.35	0.39	N/D
After Filter	<0.15	N/D	N/D
<b>Total Respirable</b>	<b>&lt;5.9</b>	<b>60.4</b>	<b>27.0</b>
<b>Total Systemic</b>	<b>&lt;2.1</b>	<b>41.4</b>	<b>9.21</b>
Cone	N/A	0.40	0.94
Induction Port	N/A	12.7	44.0
Adapter	N/A	12.4	11.3

\*As percent of emitted dose through device. Cascade Impactor operated at ca. 60 L/min.

The results indicate that the nanoparticulate budesonide powder delivered

5 60.4% of the dose to the respirable regions of the impactor, while only 27% of the micronized drug was delivered to the same region. Furthermore, 41.4% of the nanoparticulate aggregates were found in the region corresponding to alveolar lung deposition, in contrast to only 9.21% for the micronized material. Thus, the spray-dried nanoparticulate aggregates were more efficiently aerosolized than the micronized drug.

10 About 450% more *in vitro* deposition was observed within the systemic region for the nanoparticulate aggregates as compared to the micronized drug blend (measured as percent of delivered dose). Electron micrographs of the nanoparticulate and micronized dry substance formulations are shown in Figure 7.

Example 7

The purpose of this example was to demonstrate the production of freeze-dried nanoparticulate drug compositions for use in aerosol formulations.

10.0% (w/w) of a novel anti-emetic, 2.00% (w/w) of Poloxamer 188® (a 5 surface modifier), 0.500% (w/w) PVP C-15, and 87.5% (w) of Sterile Water for Injection was milled in the presence of 500 µm SDy-20 polymeric media for a period of 2 hours. A composition having a mean particle size of 286 nm, with 90% of the particles having a size of less than 372 nm, was determined via the Horiba LA-910 particle sizer. This material was then diluted to 5 % (w/w) drug with Sterile Water for Injection and 10 subjected to 60 minutes milling with 50 µm SDy-20 media. The final particle size obtained was 157 nm, with 90 % of the drug particles having a size of less than 267 nm, as determined via the Horiba LA-910. This dispersion was then utilized in a series of freeze-drying experiments below.

15 The freeze-dryer utilized was an FTS Dura-Stop system with operating parameters as follows:

Product freeze temperature: -30°C (2 hours hold)

Primary Drying:

1. Shelf temperature set: -25°C  
Chamber vacuum: 100 mT  
20 Hold time: 2000 min.
2. Shelf temp.: -10°C  
Chamber vacuum: 100 mT  
Hold time: 300 min.
3. Shelf temp.: 0°C  
Chamber vacuum: 100 mT  
25 Hold time: 300 min.
4. Shelf temp.: 20°C  
Chamber vacuum: 50 mT  
Hold time: 800 min.

30

**Example 7A**

The following freeze-dried material was reconstituted in deionized water and examined for particle size distribution via the Horiba LA-910 particle analyzer:

5      5.00% (w/w) novel anti-emetic, 5.00% (w/w) dextrose, 1.00% (w/w) Poloxamer 188®,  
0.250% (w/w) PVP C-15, and 88.8% (w/w) Sterile Water for Injection.

The average particle size of the reconstituted nanoparticulate dispersion was 4.23  $\mu\text{m}$ , with 90% of the particles having an average particle size of less than 11.8  $\mu\text{m}$ . The resultant material demonstrates that aggregates were present in the freeze-dried material having suitable particle sizes for pulmonary deposition. *See Figure 8*, which  
10 shows the particle size distribution of the freeze-dried anti-emetic aerosol. (For this example, the particle sizes were measured by weight.)

**Example 7B**

The following freeze-dried material was reconstituted in deionized water  
15 and examined for particle size distribution via the Horiba LA-910 particle analyzer:

1.00% (w/w) novel anti-emetic, 5.00% (w/w) mannitol, 0.200% (w/w) Poloxamer 188,  
0.050% (w/w) PVP C-15, and 93.8% (w/w) Sterile Water for Injection.

The resultant powder when reconstituted demonstrated an average particle size of 2.77  $\mu\text{m}$ , with 90% of the drug particles having an average particle size of less  
20 than 7.39  $\mu\text{m}$ . Thus, aggregates of the nanoparticulate anti-emetic have a particle size within an acceptable range for pulmonary deposition after patient inhalation. *See Figure 9*, which shows the particle size distribution of the freeze-dried anti-emetic aerosol. Also, if larger aggregates are generated (beyond about 5 to about 10  $\mu\text{m}$ ), jet-milling may be employed to decrease the particle size distribution of the system for pulmonary  
25 indications.

All of the dry powder inhalation systems can be utilized in either unit dose or multi-dose delivery devices, in either DPIs or pMDIs, and in nebulizer systems.

**Example 8**

The purpose of this prophetic example is to demonstrate the production of a propellant-based pMDI. This aerosol dosage form for pulmonary deposition has been the most routinely prescribed for asthma indications. The system is pressurized by using 5 a propellant, such as a CFC or HFA (hydrofluorinated alkane), which functions as the delivery medium for a micronized drug. Additionally, a valve lubricant is present. These are typically the only components for suspension-based pMDIs. The micronized drug is jet-milled to the appropriate size for lung deposition (about 3 to about 5  $\mu\text{m}$ ).

In contrast, the present invention is directed to the use of either discrete 10 nanoparticles or aggregates of nanoparticles. For preparation of discrete nanoparticulate drug, a non-aqueous milling medium is used, comprised of a high boiling point propellant. By employing a CFC-11 or trichloromonofluoromethane milling medium, nanoparticulate drug with suitable modifier can be made in a non-pressurized milling system. For example, the boiling point of CFC-11 is 23.7°C (according to the Merck 15 Index). Thus, by maintaining the milling chamber temperature below 23.7°C, the CFC-11 remains intact during the size reduction process without developing internal pressure.

After the size reduction process, the propellant can be evaporated and reclaimed in a condenser. The resultant powder of nanoparticulate drug and surface modifier can then be resuspended in non-CFC propellants. Compounds HFA-134a 20 (tetrafluoroethane) and HFA-227 (heptafluoropropane) (Solvay Fluorides, Inc., Greenwich, CT; Dupont Fluorochemicals, Wilmington, DE) are the most widely recognized non-CFC propellants. These can be pressure-filled into canisters containing the nanoparticulate drug and surface modifier.

**25 Example 8A**

The purpose of this example was to prepare a nanoparticulate aerosol formulation in a non-aqueous, non-pressurized milling system.

The following material was subjected to milling for 1.5 hrs with SDy-20 30 500  $\mu\text{m}$  polymeric media: 5.00% (w/w) triamcinolone acetonide (TA), 0.500% (w/w) Span 85® (surface modifier), and 94.5% (w/w) CFC-11. The resultant dispersion was

then harvested and the propellant evaporated. A scanning electron micrograph was taken of the resultant powder to inspect for size reduction of the drug crystals. *See Figure 10.* Significant size reduction of drug particles was observed, and a large population of smaller drug crystals was found to be present. This material is of sufficient size to be 5 respirable for inhaled administration via a pMDI or DPI system.

An exemplary corticosteroid formulation can comprise the following:  
0.066% (w/w) nanoparticulate TA, 0.034% (w/w) Span 85, and 99.9% HFA-134a.  
Assuming a product density of 1.21 g/ml and a 50  $\mu$ l metering valve, a theoretical  
delivery of 40  $\mu$ g TA is achieved. If necessary, this quantity can be modified to  
10 compensate for actuator efficiency. Ideally, the nanoparticulate powder can be dispensed  
into an appropriate container, followed by pressurized propellant filling, or a bulk slurry  
can be prepared and introduced into the final form by cold filling or pressure filling.

#### Example 9

15 The purpose of this example was to describe the use of a nanoparticulate aerosol in a propellant system operating at pressurized conditions. A pressurized system allows the processing to progress at ambient room temperature.

20 The milling is conducted using either ball milling with ceramic/glass media or high-energy Dyno-milling with modifications to contain approximately 100 psig. The intent is to load the unit with chilled propellant and seal the sample ports. Thus, if the mill or roller bottle is at room temperature, the propellant will vaporize to maintain equilibrium within the containment system. A balance will be made between propellant in a liquid state and in a vapor state. This allows for milling in a liquid medium (the propellant) at temperatures above the propellant's boiling point.

25 Exemplary useful non-chlorinated propellants include HFA-134a (tetrafluoroethane), comprising about 50 to about 99.9% of final product weight, milling within pressure at/below 100 psig, and temperatures at/below 25°C; and HFA-227 (heptafluoropropane), comprising about 50 to about 99.9% of final product weight, milling within pressure at/below 53 psig, and temperatures at/below 25°C. In addition, 30 chlorinated propellants can be used in this embodiment. Exemplary chlorinated

propellants include Freon-12 (dichlordinfluoromethane), comprising about 50 to about 99.9% of milling composition, processed within pressure at/below 85 psig, and temperatures at/below 25°C; and Freon-114 (dichlorotetrafluoroethane), comprising about 50 to about 99.9% of milling slurry, processed at pressure at/below 19 psig, and 5 temperatures at/below 25°.

#### Example 9A

In this prophetic example, the following compounds can be combined for an exemplary budesonide aerosol composition to be used in a propellant system operating 10 at pressurized conditions: 5.00% (w/w) budesonide, 0.500% PVP C-15, and 94.5% (w/w) HFA-134a.

The nanoparticulate aerosol composition would be further diluted as necessary to obtain desired delivery doses.

15 Example 9B

In this prophetic example, the following compounds can be combined for an exemplary TA aerosol composition to be used in a propellant system operating at pressurized conditions: 5.00% (w/w) TA, 0.500% PEG-400, and 94.5% (w/w) HFA-227.

20 The nanoparticulate aerosol composition would be further diluted as necessary to obtain desired delivery doses.

#### Example 10

The purpose of this example was to demonstrate the use of powders comprising spray-dried or freeze-dried nanoparticulate aggregates or discrete 25 nanoparticulate particles in propellant systems for inhalation. The MMAD of the nanoparticulate aggregates would be about 0.5  $\mu\text{m}$  to about 6.0  $\mu\text{m}$ , and the mean particle diameter of the discrete nanoparticulate drug particles would be about <1000 nm. This allows for aqueous milling and subsequent water removal. The remaining powder can then be reconstituted with a propellant, such as those listed above.

The following can be combined for use in a propellant based system for inhalation: 0.704% (w/w) nanoparticulate agent/surface modifier and 99.3% (w/w) HFA-227. The resultant nanoparticulate powder is a spray-dried aggregate with a MMAD of 2.0  $\mu$ m. Based on a theoretical product density of 1.42 g/ml and a metering valve of 100 5  $\mu$ l, a dose of 1000  $\mu$ g could be expected through-the-valve.

\* \* \* \*

It will be apparent to those skilled in the art that various modifications and variations can be made in the methods and compositions of the present invention without 10 departing from the spirit or scope of the invention. Thus, it is intended that the present invention cover the modifications and variations of this invention provided they come within the scope of the appended claims and their equivalents.

We claim:

1. An aerosol composition of an aqueous dispersion of nanoparticulate drug particles, wherein:

- 5 (a) essentially each droplet of the aerosol comprises at least one nanoparticulate drug particle;
- (b) the droplets are of a respirable size; and
- (c) the nanoparticulate drug particles comprise a poorly soluble crystalline drug, have an effective average particle size of less than about 1000 nm, and have a surface modifier adsorbed on the surface thereof.

10

2. The aerosol composition of claim 1, wherein the drug is selected from the group consisting of proteins, peptide, bronchodilators, corticosteroids, elastase inhibitors, analgesics, anti-fungals, cystic-fibrosis therapies, asthma therapies, emphysema therapies, respiratory distress syndrome therapies, chronic bronchitis therapies, chronic obstructive pulmonary disease therapies, organ-transplant rejection therapies, therapies for tuberculosis and other infections of the lung, fungal infection therapies, respiratory illness therapies associated with acquired immune deficiency syndrome, an oncology drug, an anti-emetic, an analgesic, and a cardiovascular agent.

15

3. The aerosol composition of claim 1, wherein the nanoparticulate drug particles have an effective average particle size selected from the group consisting of less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 100 nm, and less than about 50 nm.

20

4. The aerosol composition of claim 1, wherein the aerosol comprises a concentration of a drug in an amount of from about 0.05 mg/mL up to about 600 mg/mL.

25 5. The aerosol composition of claim 4, wherein the aerosol comprises a concentration of a drug selected from the group consisting of about 10 mg/mL or more,

about 100 mg/mL or more, about 200 mg/mL or more, about 400 mg/mL or more, and about 600 mg/mL.

6. The aerosol composition of claim 1, wherein the droplets of the aerosol  
5 have a MMAD of about 2 to about 10 microns.

7. The aerosol composition of claim 6, wherein the droplets of the aerosol  
have a MMAD of from about 2 to about 6 microns.

10 8. The aerosol composition of claim 1, wherein the droplets of the aerosol  
have a MMAD of less than about 2 microns.

9. The aerosol composition of claim 1, wherein the droplets of the aerosol  
have an MMAD of about 5 to about 100 microns .

15 10. The aerosol composition of claim 9, wherein the droplets of the aerosol  
have an MMAD of about 30 to about 60 microns.

11. A spray-dried powder aerosol composition comprising aggregates of  
20 nanoparticulate drug particles, wherein:

- (a) the nanoparticulate drug particles comprise a poorly soluble crystalline drug, have an effective average particle size of less than about 1000 nm, and have a surface modifier adsorbed on the surface thereof; and
- (b) the aggregates of spray-dried drug particles have a respirable size.

25 12. The aerosol composition of claim 11 further comprising a diluent.

13. The aerosol composition of claim 12, wherein essentially every diluent  
30 particle comprises at least one embedded nanoparticulate drug particle having a surface modifier adhered to the surface of the drug particle.

14. The aerosol composition of claim 11, wherein the drug is selected from the group consisting of proteins, peptides, bronchodilators, corticosteroids, elastase inhibitors, analgesics, anti-fungals, cystic-fibrosis therapies, asthma therapies, emphysema therapies, 5 respiratory distress syndrome therapies, chronic bronchitis therapies, chronic obstructive pulmonary disease therapies, organ-transplant rejection therapies, therapies for tuberculosis and other infections of the lung, fungal infection therapies, and respiratory illness therapies associated with acquired immune deficiency syndrome, an oncology drug, an anti-emetic, an analgesic, and a cardiovascular agent.

10

15. The aerosol composition of claim 11, wherein the nanoparticulate drug particles have an effective average particle size selected from the group consisting of less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 100 nm, and less than about 50 nm.

15

16. The aerosol composition of claim 11, wherein the aerosol comprises a concentration of a drug in an amount of from about 0.05 mg/g up to about 900 mg/g.

17. The aerosol composition of claim 16, wherein the aerosol comprises a 20 concentration of a drug selected from the group consisting of about 10 mg/g or more, about 100 mg/g or more, about 200 mg/g or more, about 400 mg/g or more, about 600 mg/g or more, and about 900 mg/g.

18. The aerosol composition of claim 11, wherein the aggregates of the 25 nanoparticulate drug particles have a MMAD of about 2 to about 10 microns.

19. The aerosol composition of claim 18, wherein the aggregates of the nanoparticulate drug particles have a MMAD of about 2 to about 6 microns.

20. The aerosol composition of claim 11, wherein the aggregates of the nanoparticulate drug particles have a MMAD of less than about 2 microns.

5 21. The aerosol composition of claim 11, wherein the aggregates of the nanoparticulate drug particles have a MMAD of about 5 to about 100  $\mu\text{m}$ .

10 22. The aerosol composition of claim 21, wherein the aggregates of the nanoparticulate drug particles have a MMAD of about 30 to about 60  $\mu\text{m}$ .

15 23. A freeze-dried powder aerosol composition comprising aggregates of nanoparticulate drug particles, wherein:

- (a) the aggregates of freeze-dried drug particles have a respirable particle size; and
- (b) the nanoparticulate drug particles comprise a poorly soluble crystalline drug, have an effective average particle size of less than about 1000 nm, and have a surface modifier adsorbed on the surface thereof.

24. The aerosol composition of claim 23, further comprising a diluent.

20 25. The aerosol composition of claim 23, wherein the drug is selected from the group consisting of proteins, peptides, bronchodilators, corticosteroids, elastase inhibitors, analgesics, anti-fungals, cystic-fibrosis therapies, asthma therapies, emphysema therapies, respiratory distress syndrome therapies, chronic bronchitis therapies, chronic obstructive pulmonary disease therapies, organ-transplant rejection therapies, therapies for 25 tuberculosis and other infections of the lung, fungal infection therapies, and respiratory illness therapies associated with acquired immune deficiency syndrome, an oncology drug, an anti-emetic, an analgesic, and a cardiovascular agent.

30 26. The aerosol composition of claim 23, wherein the nanoparticulate drug particles have an effective average particle size selected from the group consisting of less

than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 100 nm, and less than about 50 nm.

27. The aerosol composition of claim 23, wherein the aerosol comprises a 5 concentration of a drug in an amount of from about 0.05 mg/g up to about 900 mg/g.

28. The aerosol composition of claim 27, wherein the aerosol comprises a concentration of a drug selected from the group consisting of about 10 mg/g or more, about 100 mg/g or more, about 200 mg/g or more, about 400 mg/g or more, about 600 10 mg/g or more, and about 900 mg/g.

29. The aerosol composition of claim 23, wherein the aggregates of the nanoparticulate drug particles have a MMAD of about 2 to about 10 microns.

15 30. The aerosol composition of claim 29, wherein the aggregates of the nanoparticulate drug particles have a MMAD of about 2 to about 6 microns.

31. The aerosol composition of claim 23, wherein the aggregates of the nanoparticulate drug particles have a MMAD of less than about 2 microns.

20 32. The aerosol composition of claim 23, wherein the aggregates of the nanoparticulate drug particles have a MMAD of about 5 to about 100  $\mu\text{m}$ .

33. The aerosol composition of claim 32, wherein the aggregates of the 25 nanoparticulate drug particles have a MMAD of about 30 to about 60  $\mu\text{m}$ .

34. The aerosol composition of claim 23, further comprising spray-dried 30 nanoparticulate drug powder, wherein the drug of the freeze-dried nanoparticulate drug powder is either the same or different from the drug of the spray-dried nanoparticulate drug powder.

35. A dry powder nanoparticulate aerosol composition for use in a propellant-based pMDI comprising

5 (a) aggregates of a nanoparticulate poorly soluble crystalline drug, wherein the drug has a surface modifier adsorbed on the surface thereof, and the drug has an effective average particle size of less than about 1000 nm, wherein the aggregates have a respirable size, and

(b) a non-aqueous propellant.

10 36. The aerosol composition of claim 35, wherein the propellant is a non-CFC propellant.

37. A nanoparticulate aerosol composition for use in a propellant-based pMDI comprising

15 (a) a nanoparticulate poorly soluble crystalline drug, wherein the drug has a surface modifier adsorbed on the surface thereof, and the drug has an effective average particle size of less than about 1000 nm, and

(b) a non-aqueous propellant.

20 38. The aerosol composition of claim 37, wherein the propellant is a non-CFC propellant.

39. A method of making an aerosol of an aqueous dispersion of nanoparticulate drug particles, wherein said nanoparticulate drug particles comprise a poorly soluble crystalline drug, have an effective average particle size of less than about 25 1000 nm, and have a surface modifier adsorbed on the surface thereof; wherein the method comprises:

(a) providing an aqueous dispersion of said nanoparticulate drug particles; and

- (b) nebulizing said dispersion to form an aerosol, wherein essentially each droplet of the aerosol comprises at least one nanoparticulate drug particle and a surface modifier, and wherein the droplets are of a respirable size.

5           40. A method of making a dry powder nanoparticulate drug composition comprising:

- (a) forming an aqueous nanoparticulate dispersion of a poorly soluble drug, wherein the dispersion comprises crystalline drug particles and a surface modifier adsorbed on the surface thereof, wherein the drug particles have an effective average particle size of less than about 1000 nm;
- 10           (b) spray-drying the nanoparticulate dispersion to form a dry powder of aggregates of the nanoparticulate drug and surface modifier particles, wherein the aggregates are of a respirable size.

15           41. The method of claim 40, further comprising adding a diluent to the nanoparticulate dispersion prior to spray-drying, wherein following spray-drying essentially every diluent particle contains at least one embedded drug particle and a surface modifier.

20           42. A method of making a dry powder nanoparticulate drug aerosol formulation comprising:

- (a) milling under non-pressurized conditions a poorly soluble crystalline drug and a surface modifier in a non-aqueous medium having a high boiling point to obtain a nanoparticulate drug composition having an effective average particle size of less than about 1000 nm, and
- 25           (b) evaporating the non-aqueous medium to obtain a dry powder of aggregates of drug and surface modifier particles, wherein the aggregates are of a respirable size.

43. A method of making a nanoparticulate drug aerosol formulation comprising:

- (a) milling under pressurized conditions a poorly soluble crystalline drug and a surface modifier in a non-aqueous medium; and
- 5 (b) evaporating the non-aqueous medium to obtain a dry powder of aggregates of drug and surface modifier particles, wherein the aggregates are of a respirable size.

44. A method of making a dry powder nanoparticulate drug composition comprising:

- (a) forming an aqueous nanoparticulate dispersion of a poorly soluble drug, wherein the dispersion comprises crystalline drug particles and a surface modifier adsorbed on the surface thereof, wherein the drug particles have an effective average particle size of less than about 1000 nm;
- 15 (b) freeze-drying the nanoparticulate dispersion to form a dry powder of aggregates of the nanoparticulate drug and surface modifier particles, wherein the aggregates are of a respirable size.

45. The method of claim 44, further comprising adding a diluent to the nanoparticulate dispersion prior to freeze-drying, wherein following freeze-drying essentially every diluent particle contains at least one embedded drug particle and a surface modifier.

46. A method of administering the aerosol of claim 1 to a patient, wherein the aerosol comprises drug at a concentration of 10 mg/mL or greater, and wherein the patient delivery time for the aerosol administration is about 15 seconds or less.

47. A method of administering the aerosol of claim 11 to a patient, wherein the aerosol comprises drug at a concentration of 10 mg/g or greater, and wherein the patient delivery time for the aerosol administration is about 15 seconds or less.

48. A method of administering the aerosol of claim 23 to a patient, wherein the aerosol comprises drug at a concentration of 10 mg/g or greater, and wherein the patient delivery time for the aerosol administration is about 15 seconds or less.

5

49. A method of administering the aerosol of claim 35 to a patient, wherein the aerosol comprises drug at a concentration of 10 mg/g or greater, and wherein the patient delivery time for the aerosol administration is about 15 seconds or less.

10

50. A method of administering the aerosol of claim 37 to a patient, wherein the aerosol comprises drug at a concentration of 10 mg/g or greater, and wherein the patient delivery time for the aerosol administration is about 15 seconds or less.

## AMENDED CLAIMS

[received by the International Bureau on 10 May 2000 (10.05.00);  
original claims 1, 6-11, 18-23, 29-33, 35-37, 39, 40 and 42-44 amended;  
remaining claims unchanged (9 pages)]

1. An aerosol composition of an aqueous dispersion of nanoparticulate drug particles, wherein:
  - (a) essentially each droplet of the aerosol comprises at least one nanoparticulate drug particle;
  - (b) the droplets of the aerosol are less than or equal to about 100 microns in diameter; and
  - (c) the nanoparticulate drug particles comprise a poorly soluble crystalline drug, have an effective average particle size of less than about 1000 nm, and have a surface modifier adsorbed on the surface thereof.
2. The aerosol composition of claim 1, wherein the drug is selected from the group consisting of proteins, peptide, bronchodilators, corticosteroids, elastase inhibitors, analgesics, anti-fungals, cystic-fibrosis therapies, asthma therapies, emphysema therapies, respiratory distress syndrome therapies, chronic bronchitis therapies, chronic obstructive pulmonary disease therapies, organ-transplant rejection therapies, therapies for tuberculosis and other infections of the lung, fungal infection therapies, respiratory illness therapies associated with acquired immune deficiency syndrome, an oncology drug, an anti-emetic, an analgesic, and a cardiovascular agent.
3. The aerosol composition of claim 1, wherein the nanoparticulate drug particles have an effective average particle size selected from the group consisting of less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 100 nm, and less than about 50 nm.
4. The aerosol composition of claim 1, wherein the aerosol comprises a concentration of a drug in an amount of from about 0.05 mg/mL up to about 600 mg/mL.
5. The aerosol composition of claim 4, wherein the aerosol comprises a concentration of a drug selected from the group consisting of about 10 mg/mL or more, about

100 mg/mL or more, about 200 mg/mL or more, about 400 mg/mL or more, and about 600 mg/mL.

6. The aerosol composition of claim 1, wherein the droplets of the aerosol have a mass median aerodynamic diameter of about 2 to about 10 microns.

7. The aerosol composition of claim 6, wherein the droplets of the aerosol have a mass median aerodynamic diameter of from about 2 to about 6 microns.

8. The aerosol composition of claim 1, wherein the droplets of the aerosol have a mass median aerodynamic diameter of less than about 2 microns.

9. The aerosol composition of claim 1, wherein the droplets of the aerosol have an mass median aerodynamic diameter of about 5 to about 100 microns .

10. The aerosol composition of claim 9, wherein the droplets of the aerosol have an mass median aerodynamic diameter of about 30 to about 60 microns.

11. A spray-dried powder aerosol composition comprising aggregates of nanoparticulate drug particles, wherein:

- (a) the nanoparticulate drug particles comprise a poorly soluble crystalline drug, have an effective average particle size of less than about 1000 nm, and have a surface modifier adsorbed on the surface thereof; and
- (b) the aggregates of spray-dried drug particles are less than or equal to about 100 microns in diameter.

12. The aerosol composition of claim 11 further comprising a diluent.

13. The aerosol composition of claim 12, wherein essentially every diluent particle comprises at least one embedded nanoparticulate drug particle having a surface modifier adhered to the surface of the drug particle.

14. The aerosol composition of claim 11, wherein the drug is selected from the group consisting of proteins, peptides, bronchodilators, corticosteroids, elastase inhibitors, analgesics, anti-fungals, cystic-fibrosis therapies, asthma therapies, emphysema therapies, respiratory distress syndrome therapies, chronic bronchitis therapies, chronic obstructive pulmonary disease therapies, organ-transplant rejection therapies, therapies for tuberculosis and other infections of the lung, fungal infection therapies, and respiratory illness therapies associated with acquired immune deficiency syndrome, an oncology drug, an anti-emetic, an analgesic, and a cardiovascular agent.

15. The aerosol composition of claim 11, wherein the nanoparticulate drug particles have an effective average particle size selected from the group consisting of less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 100 nm, and less than about 50 nm.

16. The aerosol composition of claim 11, wherein the aerosol comprises a concentration of a drug in an amount of from about 0.05 mg/g up to about 900 mg/g.

17. The aerosol composition of claim 16, wherein the aerosol comprises a concentration of a drug selected from the group consisting of about 10 mg/g or more, about 100 mg/g or more, about 200 mg/g or more, about 400 mg/g or more, about 600 mg/g or more, and about 900 mg/g.

18. The aerosol composition of claim 11, wherein the aggregates of the nanoparticulate drug particles have a mass median aerodynamic diameter of about 2 to about 10 microns.

19. The aerosol composition of claim 18, wherein the aggregates of the nanoparticulate drug particles have a mass median aerodynamic diameter of about 2 to about 6 microns.

20. The aerosol composition of claim 11, wherein the aggregates of the nanoparticulate drug particles have a mass median aerodynamic diameter of less than about 2 microns.

21. The aerosol composition of claim 11, wherein the aggregates of the nanoparticulate drug particles have a mass median aerodynamic diameter of about 5 to about 100  $\mu\text{m}$ .

22. The aerosol composition of claim 21, wherein the aggregates of the nanoparticulate drug particles have a mass median aerodynamic diameter of about 30 to about 60  $\mu\text{m}$ .

23. A freeze-dried powder aerosol composition comprising aggregates of nanoparticulate drug particles, wherein:

- (a) the aggregates of freeze-dried drug particles are less than or equal to about 100 microns in diameter;
- (b) the nanoparticulate drug particles comprise a poorly soluble crystalline drug, have an effective average particle size of less than about 1000 nm, and have a surface modifier adsorbed on the surface thereof.

24. The aerosol composition of claim 23, further comprising a diluent.

25. The aerosol composition of claim 23, wherein the drug is selected from the group consisting of proteins, peptides, bronchodilators, corticosteroids, elastase inhibitors, analgesics, anti-fungals, cystic-fibrosis therapies, asthma therapies, emphysema therapies, respiratory distress syndrome therapies, chronic bronchitis therapies, chronic obstructive

pulmonary disease therapies, organ-transplant rejection therapies, therapies for tuberculosis and other infections of the lung, fungal infection therapies, and respiratory illness therapies associated with acquired immune deficiency syndrome, an oncology drug, an anti-emetic, an analgesic, and a cardiovascular agent.

26. The aerosol composition of claim 23, wherein the nanoparticulate drug particles have an effective average particle size selected from the group consisting of less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 100 nm, and less than about 50 nm.

27. The aerosol composition of claim 23, wherein the aerosol comprises a concentration of a drug in an amount of from about 0.05 mg/g up to about 900 mg/g.

28. The aerosol composition of claim 27, wherein the aerosol comprises a concentration of a drug selected from the group consisting of about 10 mg/g or more, about 100 mg/g or more, about 200 mg/g or more, about 400 mg/g or more, about 600 mg/g or more, and about 900 mg/g.

29. The aerosol composition of claim 23, wherein the aggregates of the nanoparticulate drug particles have a mass median aerodynamic diameter of about 2 to about 10 microns.

30. The aerosol composition of claim 29, wherein the aggregates of the nanoparticulate drug particles have a mass median aerodynamic diameter of about 2 to about 6 microns.

31. The aerosol composition of claim 23, wherein the aggregates of the nanoparticulate drug particles have a mass median aerodynamic diameter of less than about 2 microns.

32. The aerosol composition of claim 23, wherein the aggregates of the nanoparticulate drug particles have a mass median aerodynamic diameter of about 5 to about 100  $\mu\text{m}$ .

33. The aerosol composition of claim 32, wherein the aggregates of the nanoparticulate drug particles have a mass median aerodynamic diameter of about 30 to about 60  $\mu\text{m}$ .

34. The aerosol composition of claim 23, further comprising spray-dried nanoparticulate drug powder, wherein the drug of the freeze-dried nanoparticulate drug powder is either the same or different from the drug of the spray-dried nanoparticulate drug powder.

35. A dry powder nanoparticulate aerosol composition for use in a propellant-based pMDI comprising:

- (a) aggregates of a nanoparticulate poorly soluble crystalline drug, wherein the drug has a surface modifier adsorbed on the surface thereof, and the drug has an effective average particle size of less than about 1000 nm, wherein the aggregates are less than or equal to about 100 microns in diameter, and
- (b) a non-aqueous propellant.

36. The aerosol composition of claim 35, wherein the propellant is a non-CFC propellant.

37. A nanoparticulate aerosol composition for use in a propellant-based pMDI comprising:

- (a) a nanoparticulate poorly soluble crystalline drug, wherein the drug has a surface modifier adsorbed on the surface thereof, and the drug has an effective average particle size of less than about 1000 nm,
- (b) essentially each droplet of the aerosol comprises at least one nanoparticulate

drug particle, wherein the droplets of the aerosol generated by the pMDI have a diameter of less than or equal to about 100 microns, and

- (c) a non-aqueous propellant.

38. The aerosol composition of claim 38, wherein the propellant is a non-CFC propellant.

39. A method of making an aerosol of an aqueous dispersion of nanoparticulate drug particles, wherein said nanoparticulate drug particles comprise a poorly soluble crystalline drug, have an effective average particle size of less than about 1000 nm, and have a surface modifier adsorbed on the surface thereof; wherein the method comprises:

- (a) providing an aqueous dispersion of said nanoparticulate drug particles; and
- (b) nebulizing said dispersion to form an aerosol, wherein essentially each droplet of the aerosol comprises at least one nanoparticulate drug particle and a surface modifier, and wherein the droplets of the aerosol have a diameter of less than or equal to about 100 microns.

40. A method of making a dry powder nanoparticulate drug composition comprising:

- (a) forming an aqueous nanoparticulate dispersion of a poorly soluble drug, wherein the dispersion comprises crystalline drug particles and a surface modifier adsorbed on the surface thereof, wherein the drug particles have an effective average particle size of less than about 1000 nm;
- (b) spray-drying the nanoparticulate dispersion to form a dry powder of aggregates of the nanoparticulate drug and surface modifier particles, wherein the aggregates have a diameter of less than or equal to about 100 microns.

41. The method of claim 40, further comprising adding a diluent to the nanoparticulate dispersion prior to spray-drying, wherein following spray-drying essentially every diluent particle contains at least one embedded drug particle and a surface modifier.
42. A method of making a dry powder nanoparticulate drug aerosol formulation comprising:
  - (a) milling under non-pressurized conditions a poorly soluble crystalline drug and a surface modifier in a non-aqueous medium having a high boiling point to obtain a nanoparticulate drug composition having an effective average particle size of less than about 1000 nm, and
  - (b) evaporating the non-aqueous medium to obtain a dry powder of aggregates of drug and surface modifier particles, wherein the aggregates have a diameter of less than or equal to about 100 microns.
43. A method of making a nanoparticulate drug aerosol formulation comprising:
  - (a) milling under pressurized conditions a poorly soluble crystalline drug and a surface modifier in a non-aqueous medium; and
  - (b) evaporating the non-aqueous medium to obtain a dry powder of aggregates of drug and surface modifier particles, wherein the aggregates have a diameter of less than or equal to about 100 microns.
44. A method of making a dry powder nanoparticulate drug composition comprising:
  - (a) forming an aqueous nanoparticulate dispersion of a poorly soluble drug, wherein the dispersion comprises crystalline drug particles and a surface modifier adsorbed on the surface thereof, wherein the drug particles have an effective average particle size of less than about 1000 nm;
  - (b) freeze-drying the nanoparticulate dispersion to form a dry powder of aggregates of the nanoparticulate drug and surface modifier particles, wherein the aggregates have a diameter of less than or equal to about 100 microns.

45. The method of claim 44, further comprising adding a diluent to the nanoparticulate dispersion prior to freeze-drying, wherein following freeze-drying essentially every diluent particle contains at least one embedded drug particle and a surface modifier.

46. A method of administering the aerosol of claim 1 to a patient, wherein the aerosol comprises drug at a concentration of 10 mg/mL or greater, and wherein the patient delivery time for the aerosol administration is about 15 seconds or less.

47. A method of administering the aerosol of claim 11 to a patient, wherein the aerosol comprises drug at a concentration of 10 mg/g or greater, and wherein the patient delivery time for the aerosol administration is about 15 seconds or less.


48. A method of administering the aerosol of claim 23 to a patient, wherein the aerosol comprises drug at a concentration of 10 mg/g or greater, and wherein the patient delivery time for the aerosol administration is about 15 seconds or less.

49. A method of administering the aerosol of claim 35 to a patient, wherein the aerosol comprises drug at a concentration of 10 mg/g or greater, and wherein the patient delivery time for the aerosol administration is about 15 seconds or less.

50. A method of administering the aerosol of claim 37 to a patient, wherein the aerosol comprises drug at a concentration of 10 mg/g or greater, and wherein the patient delivery time for the aerosol administration is about 15 seconds or less.


# FIGURE 1

## *In Vitro* Deposition Pattern of Aerosolized BDP Dispersions




# FIGURE 2

## In Vitro Deposition Pattern of Nanoparticulate BDP Suspensions



3/10

## FIGURE 3



STATISTICS		PARAMETERS		UNDER	SIZE	UNDER	SIZE
Mean Size	: 1.671	Material	: SDI-naproxen	10%	1.157	90%	2.432
Standard Deviation	: 1.334	Density	: 1.26	50%	1.675		
D(4,3)	: 1.740	Run Length (sec)	: 123.9				
D(3,2)	: 1.602	PMT Voltage	: 1100.0				
Mode (Log Scale)	: 1.65	Sum of channels	: 46211				
Specific Surface Area	: 2.97 sq meter/g	Lower Size Limit	: 0.10				
		Upper Size Limit	: 200.00				
		Nozzle Type	: 700um				
		Baseline Offset	: 0.10				
		Noise Filter	: 6.00				
		Regularization	: Low				

UPPER SIZE	% IN	LOWER SIZE	% UNDER	UPPER SIZE	% IN	LOWER SIZE	% UNDER
				1.00	2.4683	0.86	1.2857
				0.86	0.8394	0.74	0.4463
				0.74	0.3050	0.63	0.1413
				0.63	0.1042	0.54	0.0371
				0.54	0.0333	0.46	0.0038
4.60	0.0000	4.00	100.00	0.46	0.0036	0.40	0.0003
4.00	0.1153	3.40	99.885	0.40	0.0003	0.34	0.0000
3.40	1.7044	2.90	98.180				
2.90	6.4095	2.50	91.771				
2.50	9.8151	2.20	81.956				
2.20	22.597	1.80	59.159				
1.80	15.436	1.60	43.923				
1.60	16.757	1.40	27.166				
1.40	14.681	1.20	12.484				
1.20	8.7303	1.00	3.7540				

4/10





FIG. 4

5/10

## FIGURE 5




SPRAY-DRIED NAPROXEN

STATISTICS		PARAMETERS		% UNDER	SIZE	% UNDER	SIZE
Mean Size	: 2.906	Material	: SDI-naproxen	10%	1.554	90%	4.651
Standard Deviation	: 1.524	Density	: 1.26	50%	3.183		
D(4,3)	: 3.142	Run Length (sec)	: 108.9				
D(3,2)	: 2.632	PMT Voltage	: 1100.0				
Mode (Log Scale)	: 3.66	Sum of channels	: 13520				
Specific Surface Area	: 1.81 sq meter/g	Lower Size Limit	: 0.10				
		Upper Size Limit	: 200.00				
		Nozzle Type	: 700um				
		Baseline Offset	: 0.10				
		Noise Filter	: 6.00				
		Regularization	: Low				

UPPER SIZE	% IN	LOWER SIZE	% UNDER	UPPER SIZE	% IN	LOWER SIZE	% UNDER
				1.00	1.0101	0.86	0.6844
				0.86	0.4335	0.74	0.2509
7.40	0.0000	6.30	100.00	0.74	0.1785	0.63	0.0723
6.30	1.1614	5.40	98.839	0.63	0.0548	0.54	0.0175
5.40	9.8645	4.60	88.974	0.54	0.0153	0.46	0.0021
4.60	13.706	4.00	75.268	0.46	0.0020	0.40	0.0001
4.00	18.274	3.40	56.994	0.40	0.0001	0.34	0.0000
3.40	15.715	2.90	41.278				
2.90	10.821	2.50	30.457				
2.50	7.2247	2.20	23.232				
2.20	8.6259	1.80	14.606				
1.80	3.7744	1.60	10.832				
1.60	3.5448	1.40	7.2871				
1.40	3.1759	1.20	4.1112				
1.20	2.4167	1.00	1.6945				

6/10

# FIGURE 6



spray dried ta.

STATISTICS				PARAMETERS				\$UNDER		SIZE		\$UNDER		SIZE	
Mean Size	:	5.540		Material	:	SDI-naproxen		10%	3.600	90%	9.082				
Standard Deviation	:	1.455		Density	:	1.26		50%	5.516						
D(4,3)	:	5.924		Run Length (sec)	:	189.6									
D(3,2)	:	5.146		PMT Voltage	:	1100.0									
Mode (Log Scale)	:	4.82		Sum of channels	:	100494									
Specific Surface Area	:	0.93	sq meter/g	Lower Size Limit	:	0.10									
				Upper Size Limit	:	200.00									
				Nozzle Type	:	700um									
				Baseline Offset	:	0.10									
				Noise Filter	:	6.00									
				Regularization	:	Off									

UPPER	%	LOWER	%												
SIZE	IN	SIZE	UNDER												
								10.0	7.5026	8.60	86.677	1.00	0.0237	0.86	0.0213
								8.60	10.326	7.40	76.352	0.86	0.0121	0.74	0.0092
								7.40	13.417	6.30	62.935	0.74	0.0064	0.63	0.0028
								6.30	14.999	5.40	47.935	0.63	0.0021	0.54	0.0006
								5.40	16.094	4.60	31.841	0.54	0.0006	0.46	0.0001
								4.60	13.547	4.00	18.295	0.46	0.0001	0.40	0.0000
								4.00	11.255	3.40	7.0394				
								3.40	1.2799	2.90	1.7595				
								2.90	1.3355	2.50	2.4240				
								2.50	0.8131	2.20	1.6109				
								2.20	0.8995	1.80	0.7114				
								1.80	0.3128	1.60	0.3985				
								1.60	0.1861	1.40	0.2125				
								1.40	0.1061	1.20	0.1063				
14.0	0.0000	12.0	100.00	12.0	5.8201	10.0	94.180	1.20	0.0613	1.00	0.0450				

7/10




FIG. 7A



FIG. 7B

8/10

# FIGURE 8

## HORIBA LA-910

Laser scattering particle size distribution analyzer

### PARTICLE SIZE MEASUREMENT DATA


Material : 5% Dextrose 4-3-98  
 Source : Reconst. water/3g fill  
 Lot Number : In water/1 min. sonication

#### Data

Median : 1.355 $\mu$ m SP.Area: 114884cm<sup>2</sup>/cm<sup>3</sup> S.D. : 5.324 $\mu$ m  
 Mode : 0.272 $\mu$ m Mean : 4.225 $\mu$ m  
 C.V. : 126.02%

Span : (D 10.0-D 90.0) / D<sub>50</sub> = 8.564

Dia. on % (90.0%)	: 11.822 $\mu$ m	% on Dia. ( 0.400 $\mu$ m)	: 41.9%
Dia. on % (50.0%)	: 1.355 $\mu$ m	% on Dia. ( 0.300 $\mu$ m)	: 31.7%
Dia. on % (95.0%)	: 14.996 $\mu$ m	% on Dia. ( 0.100 $\mu$ m)	: 0.0%
Dia. on % (80.0%)	: 8.384 $\mu$ m	% on Dia. ( 0.200 $\mu$ m)	: 5.9%
Dia. on % (70.0%)	: 5.949 $\mu$ m	% on Dia. ( 1.000 $\mu$ m)	: 48.3%



Size( $\mu$ m)	Freq(%)	Und(%)	Size( $\mu$ m)	Freq(%)	Und(%)	Size( $\mu$ m)	Freq(%)	Und(%)
26.11	0.46	99.66	0.669	0.86	46.02			
22.80	0.81	99.20	0.584	0.90	45.16			
19.90	1.29	98.39	0.510	1.03	44.26			
17.38	1.88	97.10	0.445	1.68	43.23			
15.17	2.54	95.22	0.389	3.56	41.54			
13.25	3.20	92.68	0.339	6.97	37.98			
11.56	3.76	89.48	0.296	10.10	31.01			
10.10	4.15	85.72	0.259	9.61	20.91			
8.816	4.26	81.57	0.226	6.06	11.30			
7.697	4.06	77.32	0.197	2.99	5.23			
6.720	3.63	73.26	0.172	1.31	2.24			
5.867	3.16	69.63	0.150	0.56	0.93			
5.122	2.76	66.47	0.131	0.26	0.37			
4.472	2.46	63.71	0.115	0.11	0.11			
3.905	2.16	61.25	0.100	0.00	0.00			
3.409	1.89	59.10						
2.976	1.68	57.21						
2.599	1.49	55.52						
2.269	1.24	54.03						
1.981	1.10	52.79						
1.729	0.97	51.69						
1.510	0.90	50.72						
1.318	0.80	49.82						
1.151	0.67	49.02						
1.005	0.66	48.35						
34.25	0.11	100.00	0.877	0.81	47.69			
29.91	0.24	99.89	0.766	0.86	46.88			

9/10

# FIGURE 9

## HORIBA LA-910

Laser scattering particle size distribution analyzer

### PARTICLE SIZE MEASUREMENT DATA


Material : reconst. 1%N9585, 5%Man  
 Source : In water  
 Lot Number : 1min sonication

#### Data

Median :  $1.533\mu\text{m}$  SP.Area:  $93485\text{cm}^2/\text{cm}^3$  S.D. :  $3.123\mu\text{m}$   
 Mode :  $0.276\mu\text{m}$  Mean :  $2.767\mu\text{m}$   
 C.V. : 112.86%

Span :  $(D_{10.0} - D_{90.0}) / D_{50} = 4.665$ 

Dia. on % (90.0%)	$7.392\mu\text{m}$	% on Dia. (	$0.400\mu\text{m}$ )	28.8%
Dia. on % (50.0%)	$1.533\mu\text{m}$	% on Dia. (	$0.300\mu\text{m}$ )	19.8%
Dia. on % (95.0%)	$9.346\mu\text{m}$	% on Dia. (	$0.100\mu\text{m}$ )	0.0%
Dia. on % (80.0%)	$5.011\mu\text{m}$	% on Dia. (	$0.200\mu\text{m}$ )	4.0%
Dia. on % (70.0%)	$3.416\mu\text{m}$	% on Dia. (	$1.000\mu\text{m}$ )	41.7%



Size( $\mu\text{m}$ )	Freq(%)	Und(%)	Size( $\mu\text{m}$ )	Freq(%)	Und(%)
19.90	0.11	100.00	0.669	1.75	35.66
17.38	0.27	99.89	0.584	1.65	33.91
15.17	0.57	99.61	0.510	1.67	32.26
13.25	1.04	99.04	0.445	2.22	30.59
11.56	1.66	98.00	0.389	3.60	28.36
10.10	2.35	96.34	0.339	5.49	24.76
8.816	2.98	93.99	0.296	6.54	19.28
7.697	3.38	91.01	0.259	5.59	12.74
6.720	3.53	87.62	0.226	3.52	7.15
5.867	3.52	84.09	0.197	1.87	3.63
5.122	3.51	80.57	0.172	0.93	1.76
4.472	3.55	77.06	0.150	0.46	0.84
3.905	3.56	73.50	0.131	0.25	0.38
3.409	3.53	69.94	0.115	0.13	0.13
2.976	3.54	66.41	0.100	0.00	0.00
2.599	3.51	62.87			
2.269	3.33	59.36			
1.981	3.27	56.03			
1.729	3.10	52.76			
1.510	3.00	49.66			
1.318	2.70	46.66			
1.151	2.24	43.96			
1.005	2.02	41.73			
0.877	2.09	39.71			
0.766	1.95	37.62			

10/10




FIG. 10

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A61K9/14 A61K9/72

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 25918 A (NANOSYSTEMS L.L.C.) 29 August 1996 (1996-08-29) page 2, line 25 -page 3, line 5 page 3, line 15 -page 5, line 11 page 18 -page 24; example 1 —	1-10, 39, 46-50
Y	US 5 518 738 A (EICKHOFF ET AL.) 21 May 1996 (1996-05-21)	11-22, 35-38, 43
X	column 6, line 51 -column 7, line 6 —	40, 41
X	WO 98 35666 A (NANOSYSTEMS LLC) 20 August 1998 (1998-08-20) page 14, line 5 - line 29 —	40
Y	WO 95 27475 A (ABBOTT LABORATORIES) 19 October 1995 (1995-10-19) page 3, line 10 -page 6, line 5 —	11-22, 35-38, 43
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

10 April 2000

Date of mailing of the international search report

18/04/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentstaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Benz, K

## INTERNATIONAL SEARCH REPORT

International Filing No

PCT/US 99/26799

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 99 38493 A (RTP PHARMA INC.) 10 June 1999 (1999-06-10) page 7, line 5 -page 17 -----	35-38

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/ 26799

### Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  
**Remark:** Although claims 46-50 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

## Information on patent family members

International application No  
PCT/US 99/26799

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
WO 9625918	A 29-08-1996	AU 4990696	A	11-09-1996	
		CA 2213638	A	29-08-1996	
		EP 0810853	A	10-12-1997	
US 5518738	A 21-05-1996	AT 174506	T	15-01-1999	
		AU 4900996	A	27-08-1996	
		CA 2212779	A	15-08-1996	
		DE 69601158	D	28-01-1999	
		DE 69601158	T	22-07-1999	
		EP 0808156	A	26-11-1997	
		ES 2125099	T	16-02-1999	
		JP 10513198	T	15-12-1998	
		WO 9624339	A	15-08-1996	
WO 9835666	A 20-08-1998	NONE			
WO 9527475	A 19-10-1995	US 5711934	A	27-01-1998	
		CA 2186895	A	19-10-1995	
		EP 0755245	A	29-01-1997	
		JP 9511661	T	25-11-1997	
		US 5687920	A	18-11-1997	
WO 9938493	A 05-08-1999	AU 2024499	A	16-08-1999	

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**